

FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008

```
=> fil reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          0.84      0.84
```

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4
DICTIONARY FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> s
[idek][eqq][lra][nds][alki][ly][rnk][yn]h[mig][vlqg][gktd][rsle][raei][vmtl][lcv][t
ags]/sqsp
```

INVALID BRACKET EXPRESSION

```
=> fil reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          1.38      2.22
```

FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4
DICTIONARY FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s
[idek][eaq]l[lra][nds][alki][ly][rnk][yn]h[mig][vlqg][gktd][rsle][raei][vmtl][lcv][
tags]/sqsp

L1 125 [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNK][YN]H[MIG][VLQG][GKTD][RSL
E][RAEI][VMTL][LCV][TAGS]/SQSP

=> fil caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	30.86	33.08

FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13
FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> s l1
L2 78 L1

=> s l1/thu
L3 26 L1/THU

=> d ti 1-26

L3 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2008 ACS ON STN
TI Use of β ig-h3 protein comprising fas-1 domains, EM1 domain and RGD motifs for treatment and prevention of angiogenesis-related disorders

L3 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2008 ACS ON STN

T1 Prevention and treatment of inflammation by inhibiting FEX-2-dependent adhesion of lymphocytes to the endothelium

L3 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Differentially expressed nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

L3 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening

L3 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

L3 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 TAT (Tumor-associated Antigenic Target) polypeptides and methods for diagnosis and treatment of tumors of glial origin

L3 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer

L3 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L3 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases

L3 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L3 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Nucleic acid and encoded protein sequences that are differentially expressed in psoriatic skin and their use for diagnosis and treatment of psoriasis

L3 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Human protein and cDNA sequences for diagnostics and therapeutics

L3 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Methods of testing for bronchial asthma or chronic obstructive pulmonary disease, and drug screening for the same, using identified differentially expressed IL-13-stimulated marker genes

L3 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Genetic and protein manipulation of β ig-H3 for the treatment and cure of muscular dystrophies

L3 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L3 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L3 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

T1 Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma
 L3 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 T1 Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
 L3 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 T1 Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer
 L3 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 T1 Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses
 L3 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 T1 Protein-protein interactions in human adipocyte cells and method for selecting modulators of these interactions
 L3 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 T1 Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer
 L3 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 T1 Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer
 L3 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 T1 Nucleic acids and their encoded polypeptides from human tissues
 L3 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 T1 Identification of colon cancer-associated proteins for immunotherapy and diagnosis
 L3 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 T1 Colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

11.96

45.04

FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4

DICTIONARY FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s l1 and sql<30

L4 0 L1 AND SQL<30

=> d his

(FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008

L1 FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008
125 S [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNLK][YN]H[MIG][VLQG][GKTD] [

L1 FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008

L2 78 S L1

L3 26 S L1/THU

L1 FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008

L4 0 S L1 AND SQL<30

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

6.07

51.11

FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13

FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> s US20070004622/pn

L5 1 US20070004622/PN

=> analyze l5 1 rn

L6 ANALYZE L5 1 RN : 10 TERMS

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.25	65.36

FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4
DICTIONARY FILE UPDATES: 23 SEP 2008 HIGHEST RN 1052062-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> s l6

L7 10 L6

=> s l1 and l6

L9 10 L1 AND L8

=> d scan

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 8: PN: WO2004087193 SEQID: 8 unclaimed protein (9CI)
SQL 113
MF Unspecified
CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5: PN: WO2004087193 SEQID: 5 unclaimed protein (9CI)
SQL 131
MF Unspecified
CI MAN

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2: PN: WO2004087193 SEQID: 2 unclaimed protein (9CI)
SQL 103
MF Unspecified
CI MAN

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 9: PN: WO2004087193 SEQID: 9 unclaimed protein (9CI)
SQL 73
MF Unspecified
CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 6: PN: WO2004087193 SEQID: 6 unclaimed protein (9CI)
SQL 85
MF Unspecified
CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3: PN: WO2004087193 SEQID: 3 unclaimed protein (9CI)
SQL 131
MF Unspecified
CI MAN

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 10: PN: WO2004087193 SEQID: 10 unclaimed protein (9CI)
SQL 67
MF Unspecified
CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 7: PN: WO2004087193 SEQID: 7 unclaimed protein (9CI)
SQL 119
MF Unspecified
CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4: PN: WO2004087193 SEQID: 4 unclaimed protein (9CI)
SQL 129
MF Unspecified
CI MAN

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 10 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1: PN: WO2004087193 SEQID: 1 unclaimed protein (9CI)
SQL 683
MF Unspecified
CI MAN

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

ALL ANSWERS HAVE BEEN SCANNED

=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008

FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008

L1 125 S [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNLK][YN]H[MIG][VLQG][GKTD][

FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008

L2 78 S L1

L3 26 S L1/THU

FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008
L4 0 S L1 AND SQL<30

FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008
L5 1 S US20070004622/PN
L6 ANALYZE L5 1 RN : 10 TERMS

FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008
L7 10 S L6
L8 10 S L6
L9 10 S L1 AND L8

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	65.82

FILE 'CAPLUS' ENTERED AT 14:53:35 ON 24 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13
FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> s tumor or tumour
L10 297112 TUMOR/OBI OR TUMOUR/OBI

=> s onco?
L11 45619 ONCO?/OBI

=> s neoplasm
L12 525362 NEOPLASM/OBI

=> s cancer
L13 246205 CANCER/OBI

=> s carcino?
L14 223599 CARCINO?/OBI

```

=> s 110-114
L15      782082 (L10 OR L11 OR L12 OR L13 OR L14)

=> d his

(FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008

FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008
L1      125 S [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNLK][YN]H[MIG][VLQG][GKTD][

FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008
L2      78 S L1
L3      26 S L1/THU

FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008
L4      0 S L1 AND SQL<30

FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008
L5      1 S US20070004622/PN
L6      ANALYZE L5 1 RN :      10 TERMS

FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008
L7      10 S L6
L8      10 S L6
L9      10 S L1 AND L8

FILE 'CAPLUS' ENTERED AT 14:53:35 ON 24 SEP 2008
L10     297112 S TUMOR OR TUMOUR
L11     45619 S ONCO?
L12     525362 S NEOPLASM
L13     246205 S CANCER
L14     223599 S CARCINO?
L15     782082 S L10-L14

=> s 13 (1) 115
L16     16 L3 (L) L15

=> d ti 1-16

L16     ANSWER 1 OF 16 CAPLUS COPYRIGHT 2008 ACS ON STN
TI      Differentially expressed nucleic acids and encoded polypeptides for use in
        liver disorders and epithelial cancer

L16     ANSWER 2 OF 16 CAPLUS COPYRIGHT 2008 ACS ON STN
TI      Expression profile of colon cancer specific genes and their use as
        biomarkers for diagnosis, therapy and drug screening

L16     ANSWER 3 OF 16 CAPLUS COPYRIGHT 2008 ACS ON STN
TI      Genes showing altered patterns of expression in colon cancer and their use
        in diagnosis and therapy

L16     ANSWER 4 OF 16 CAPLUS COPYRIGHT 2008 ACS ON STN
TI      TAT (Tumor-associated Antigenic Target) polypeptides and methods for
        diagnosis and treatment of tumors of glial origin

L16     ANSWER 5 OF 16 CAPLUS COPYRIGHT 2008 ACS ON STN
TI      Novel human genes and gene expression products and their use in diagnosis
        and treatment of colon cancer

```

L16 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L16 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L16 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L16 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L16 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L16 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L16 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L16 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L16 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L16 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Identification of colon cancer-associated proteins for immunotherapy and diagnosis

L16 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer

=> d ti 15

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Use of a peptide that interacts with alphav beta3 integrin of endothelial cell

=> s l16 or 15
 L17 17 L16 OR L5

=> d ti 1-17

L17 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Differentially expressed nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

L17 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening

L17 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

L17 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI TAT (Tumor-associated Antigenic Target) polypeptides and methods for diagnosis and treatment of tumors of glial origin

L17 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Use of a peptide that interacts with alpha v beta3 integrin of endothelial cell

L17 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer

L17 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L17 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L17 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L17 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L17 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L17 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L17 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L17 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L17 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L17 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Identification of colon cancer-associated proteins for immunotherapy and diagnosis

L17 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Colon tumor-specific nucleic acids and proteins and their use for
 immunotherapy and diagnosis of colon cancer

=> d ibib abs hitseq 17

L17 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:441937 CAPLUS <<LOGINID:20080924>>
 DOCUMENT NUMBER: 133:85149
 TITLE: Colon tumor-specific nucleic acids and proteins and
 their use for immunotherapy and diagnosis of colon
 cancer
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather;
 Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John;
 Wang, Tongtong; Jiang, Yuqiu
 PATENT ASSIGNEE(S): Corixa Corporation, USA
 SOURCE: PCT Int. Appl., 229 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
CA 2356987	A1	20000629	CA 1999-2356987	19991223
EP 1144632	A2	20011017	EP 1999-967625	19991223
EP 1144632	A3	20011107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533082	T	20021008	JP 2000-589697	19991223
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020076414	A1	20020620	US 2001-922217	20010803
US 20020182191	A1	20021205	US 2001-25380	20011219
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:				
			US 1998-221298	A 19981223
			US 1999-347496	A 19990702
			US 1999-401064	A 19990922
			US 1999-444242	A 19991119
			US 1999-454150	A 19991202
			US 1999-444252	A2 19991119
			WO 1999-US30909	W 19991223
			US 1999-476296	A2 19991230
			US 2000-480321	A2 20000110
			US 2000-504629	A2 20000215
			US 2000-519444	A2 20000306
			US 2000-444252	A2 20000410
			US 2000-575251	A2 20000519

US 2000-609448 A2 20000629
US 2000-649811 A2 20000828
US 2001-833263 A2 20010410
US 2001-922217 A2 20010803
US 2001-25380 B1 20011219

AB Over 470 nucleic acids that are overexpressed ≥ 2 -fold in human colon tumor tissues are provided. Complementary DNA libraries were constructed by subtracting a pool of colon tumors with a pool of normal colon and other tissues using PCR subtraction methodologies; clones from the cDNA subtracted library were submitted to PCR amplification, and mRNA expression levels for representative clones determined by microarray technol. This method recovers rare transcripts that are over-expressed in colon tumor tissue. Addnl. colon tumor-specific transcripts were obtained by (1) conventional cDNA subtraction, (2) use of mouse antisera to identify DNA sequences encoding colon tumor antigens, (3) and isolation of tumor polypeptides using SCID-passaged tumor RNA. Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen-presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 148710-76-3, Protein (human clone β ig-h3 transforming growth factor β -induced precursor reduced)
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer)

RN 148710-76-3 CAPLUS

CN Protein (human clone β ig-h3 transforming growth factor β -induced precursor reduced) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
51 VQKVIQTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPPAA
101 LPLSNLYETL GVGVSITTQL YDTRTEKLRP EMEGPGSFTI FAPSNEAWAS
151 LPAEVLDSLVS SNVNIELLNA LRYHMVGRRV LTDELKHGMT LTSMYQNSNI
201 QIHHYPNGIV TVNCARLLKA DHHATNGVVH LIDKVISITIT NNIQIIEIE
251 DTFETLRAAV AASGLNTMLE GNGQYITLLAP TNEAFEKIPS ETLNRLIGDP
301 EALRDLNHNH ILKSAMCAEA IVAGLSVETL EGTTLVGCSS GDMLTINGKA
351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST ADLFRQAGL
401 GNHLSGSESL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KQLASKYLY
451 HGQTLETLLG KKLRFVYVRN SLCIENS CIA AHDKRGRYGT LFTMDRVLTP
501 PMGTVMVDLKV GDNRF5MLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGGKLEVS
601 LKNNVVSVNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

=> fil stng
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST	35.15	100.97
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.80	-0.80

FILE 'STNGUIDE' ENTERED AT 14:55:58 ON 24 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Sep 19, 2008 (20080919/UP).

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.72	101.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.80

FILE 'CAPLUS' ENTERED AT 15:02:52 ON 24 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13
 FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>
 'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d ibib abs hitseq 6-16

L17 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2004:609831 CAPLUS <<LOGINID:20080924>>
 DOCUMENT NUMBER: 141:155365
 TITLE: Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer
 INVENTOR(S): Astle, Jon H.; Boardman, Lisa Allyn; Burgart, Lawrence J.; Burgess, Christopher C.; Catino, Theodore J.; Dwivedi, Poornima; Lewis, Marcia E.; Molino, Gary A.; Myerow, Susan H.; Thiagalingam, Arunthathi; Thibodeau,

PATENT ASSIGNEE(S): Stephen N. Bayer Healthcare LLC, USA; Mayo Foundation for Medical Education & Research

SOURCE: U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of U.S. Ser. No. 871,161.

DOCUMENT TYPE: CODEN: USXXCO

LANGUAGE: Patent

FAMILY ACC. NUM. COUNT: English

PATENT INFORMATION: 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040146879	A1	20040729	US 2003-610049	20030630
US 6262333	B1	20010717	US 1999-328111	19990608
US 6262334	B1	20010717	US 1999-385982	19990830
US 20030097666	A1	20030522	US 2001-871161	20010531
US 20020144298	A1	20021003	US 2001-879536	20010611
EP 1494031	A2	20050105	EP 2004-253880	20040629
EP 1494031	A3	20071121		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2005046137 A 20050224 JP 2004-191089 20040629

PRIORITY APPLN. INFO.:

US 1998-98639P	P	19980831
US 1999-117393P	P	19990127
US 1999-328111	A2	19990608
US 1999-385982	A1	19990830
US 2001-871161	A2	20010531
US 1998-88801P	P	19980610
US 2003-610049	A	20030630

AB This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly in colon cancer tissue.

IT 727761-71-9

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; human genes and gene expression products and their use in diagnosis and treatment of colon cancer)

RN 727761-71-9 CAPLUS

CN Protein (human colon cancer-specific gene) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPVNCA

51 VQKVIQTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA

101 LPLSNLYETL GVGVSITTQL YDTRTEKLRP EMEGPGSFTI FAPSNEAWAS

151 LPAEVLDSL V SNVNIELLNA LRYHMVGRVR LTDELKHGMT LTSMYQNSNI

201 QIHHPNGIV TVNRCARLKA DHHAATNGVVH LIDKVISIT NIINQIIEIE

251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRLGDP

301 EALRDLNLNH ILKSAMCAEA IVAGLSVETL EGTILEVGCS GDMILINGKA

351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLPQAGL

401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KQGLASKYLY

451 HGQTLETLLG KKLRFVYVRN SLCIENS CIA AHDKRGRYGT LFTMDRVLT

501 PMGTVMVDLKG GDNRFSLMVA AIQSAGLTET LNREGVYTVF APTNEAFRAL

551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKELEVS

601 LKNNVVSUNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA

651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:534405 CAPLUS <<LOGINID:20080924>>
 DOCUMENT NUMBER: 141:69775
 TITLE: Specific protein markers useful for diagnosis of
 pancreatic cancer and screening methods
 INVENTOR(S): Chen, Jie; Hu, Liping; Liu, Tong Hua; Lu, Zhao Hui;
 Shen, Yan
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.; Sinogenomax Co. Ltd.
 Chinese National Human Genomecenter
 SOURCE: PCT Int. Appl., 381 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055519	A2	20040701	WO 2003-EP14057	20031211
WO 2004055519	A3	20041104		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003294828	A1	20040709	AU 2003-294828	20031211
US 20040219572	A1	20041104	US 2003-733969	20031211
CN 1726395	A	20060125	CN 2003-80106539	20031211
PRIORITY APPLN. INFO.:			EP 2002-28058	A 20021217
			EP 2003-25237	A 20031105
			WO 2003-EP14057	W 20031211
AB	The present invention provides polypeptides which are up- or down-regulated in pancreatic cancer and which can be used as markers for diagnosis of pancreatic cancer. Thus, 110 protein markers are identified in pancreatic adenocarcinoma patients by 2-dimensional electrophoresis and MALDI-TOF mass spectrometry. The invention also provides an in vitro method for the diagnosis of pancreatic cancer and/or the susceptibility to pancreatic cancer comprising the steps of (a) obtaining a biol. sample; and (b) detecting and/or measuring the increase of one or more polypeptides as disclosed herein. Furthermore, screening methods relating to inhibitors and antagonists of the specific polypeptides disclosed herein are provided.			
IT	712410-93-0 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; specific protein markers useful for diagnosis of pancreatic cancer and screening methods)			
RN	712410-93-0 CAPLUS			
CN	Cell adhesion molecule β ig-h3 (TGF- β -induced gene h3 (human precursor) (9CI) (CA INDEX NAME)			

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVGITNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPEGEKCPAA
 101 LPLSNLYETL GVGSTTTQL YTDRTKLRP EMEGPGSFTI FAPSNEAWAS
 151 LPAEVLDSL SVNNIELLNA LRYHMVGRVR LTDELKHGMT LTSMYQNSNI
 201 QIHHPNGIV TVNCARLLKA DHHATNGVVH LIDKVVISTIT NNIQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFKIPS ETLNRLILGDP
 301 EALRDLNHNH ILKSAMCAEA IVAGLSVETL EGTILEVGCS GDMLTINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFQAGL
 401 GNHLSGSSER TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKVLY
 451 HGQTLETGG KKLRFVYVRN SLCIENSCIA AHDKRGYGT LFTMDRVLTP
 501 PMGTVMIDLK GDNRFMSMLVA AIQASAGLTET LNRGVYIVF APTNEAFRAL
 551 PPRSRRLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKEVLS
 601 LKNNVSVNKK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2004:308357 CAPLUS <<LOGINID:20080924>>
 DOCUMENT NUMBER: 140:333596
 TITLE: Differentially expressed nucleic acids and their
 encoded proteins and their uses for the diagnosis and
 treatment of tumor
 INVENTOR(S): Wu, Thomas D.; Zhang, Zemin; Zhou, Yan
 PATENT ASSIGNEE(S): Genentech, Inc., USA
 SOURCE: PCI Int. Appl., 7273 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030615	A2	20040415	WO 2003-US28547	20030929
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2500687	A1	20040415	CA 2003-2500687	20030929
WO 2004030615	A2	20040415	WO 2003-XA28547	20030929
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003295328	A1	20040423	AU 2003-295328	20030929
EP 1594447	A2	20051116	EP 2003-786510	20030929
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006516089 T 20060622 JP 2004-541530 20030929
 US 20070224201 A1 20070927 US 2005-529351 20050325
 PRIORITY APPLN. INFO.: US 2002-414971P P 20021002
 WO 2003-US28547 W 20030929

AB The present invention provides a large number of specific cDNA sequences which are upregulated in certain tumor tissues as compared to their normal tissue counterparts and therefore useful for the diagnosis and treatment of tumor in mammals. An expressed sequence tag (EST) DNA database was searched and interesting EST sequences identified by GEPIS (gene expression profiling in silico), a bioinformatics tool that characterizes genes of interest for new cancer therapeutic targets. Using this type of screening bioinformatics, various tumor-associated antigenic target (TAT) proteins (and their encoding nucleic acid mols). were identified as being significantly overexpressed in particular type of cancer or certain cancers as compared to other cancers and/or normal non-cancerous tissues. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints].

IT 67/367-06-5P, Tumor-associated antigen PRO2561 (human)
 RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence; differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor)

RN 67/367-06-5 CAPLUS
 CN Tumor-associated antigen PRO2561 (human) (9CI) (CA INDEX NAME)

SEQ 1 MMALFVRLLA LALALALGPA ATLAGPAKSP YQLVLQHSRL RGRQHPNVN
 51 AVQKVIGTNR KYFTNCKQWY QRKICGKSTV ISYECCPGYE KVPGEKGCPA
 101 ALPLSNLYET LGVVGSTTTQ LYTDRTKLRL PEMEGPGSFT IFAPNEAWA
 151 SLPAEVLDSL VSNVNIELLN ALRYHVMVGR VLTDELKHGM TLTSMYQNSN
 201 IQIHYPNGI VTNCARLLK ADHHATNGV VHLIDKVISTI TNNIQIIEI
 251 EDTFETLRAA VAASGLNTML EGNGQYTLLA PTNEAFKIP SETLNRILGD
 301 PEALRDLNHN HILKSAMCAE AIVAGLSVET LEGTTLEVGC SGMMLTINGK
 351 AIISNKDILA TNGVIHYIDE LLIPDSAKTL FELAAESDVS TAIDLFRQAG
 401 LGNHLSSGER LTLAPLNSV FKDGTPPIDA HTRNLLRNHI IKDQLASKYL
 451 YHGQTLLETLG GKLLRVFVYR NSLCIENSCI AAHDKRGYRG TLTFTMDRVLT
 501 PPMGTVMYDVL KGDNRFSMLV AAIQSAGLTE TLNREGVYTV FAPTNEAFRA
 551 LPPRSRSLG DAKELANIL KYHIGDEILV SGGIGALVRL KSLQGDKLEV
 601 SLKNNVSVN KEPVAEPDIM ATNGVVHVIT NVLQPPANRP QERGDELADS
 651 ALEIFKQASA FSRASQRSVR LAPVIQKLE RMKH

L17 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2003:747872 CAPLUS <<LOGINID::20080924>>
 DOCUMENT NUMBER: 139:256367
 TITLE: Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather; Meagher, Madeleine Joy; Stolk, John; Benson, Darin R.; Wang, Tongtong
 PATENT ASSIGNEE(S): Corixa Corporation, USA
 SOURCE: U.S., 140 pp., Cont.-in-part of U.S. Ser. No. 347,496.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6623923	B1	20030923	US 1999-401064	19990922
US 6284241	B1	20010904	US 1998-221298	19981223
CA 2356987	A1	20000629	CA 1999-2356987	19991223
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1144632	A2	20011017	EP 1999-967625	19991223
EP 1144632	A3	20011107		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002533082	T	20021008	JP 2000-589697	19991223
EP 1715043	A2	20061025	EP 2006-2432	19991223
EP 1715043	A3	20070110		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
EP 1767636	A2	20070328	EP 2006-25304	19991223
EP 1767636	A3	20070613		
R:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, AL, LT, LV, MK, RO, SI			
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020076414	A1	20020620	US 2001-922217	20010803
US 20020182191	A1	20021205	US 2001-25380	20011219
US 20050260177	A1	20051124	US 2005-108172	20050415

PRIORITY APPLN. INFO.:

US 1998-221298	A2	19981223
US 1999-347496	A2	19990702
US 1999-401064	A	19990922
US 1999-444242	A	19991119
US 1999-444252	A2	19991119
US 1999-454150	A	19991202
EP 1999-967625	A3	19991223
WO 1999-US30909	W	19991223
US 1999-476296	A2	19991230
US 2000-480321	A2	20000110
US 2000-504629	A2	20000215
US 2000-519444	A2	20000306
US 2000-444252	A2	20000410
US 2000-575251	A2	20000519
US 2000-609448	A2	20000629
US 2000-649811	A2	20000828
US 2001-833263	A2	20010410
US 2001-922217	A2	20010803
US 2001-25380	B1	20011219

AB Compsns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compsns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides

differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such comps. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 603206-84-4P
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence; tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer)
 RN 603206-84-4 CAPLUS
 CN Colon tumor-associated protein (human clone US6623923-SEQID-121) (9CI)
 (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPVCA
 51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGPAA
 101 LPLSNLYETL GVGSTTTQL YTDRTKLRP EMEGPGSFTI FAPSNEAWAS
 151 LPAEVLDSL SVNVIELLNA LRYHVMGRRV LTDELKHGMT LTSMYQNSNI
 201 QIHHYPNGIV TVNCARLLKA DHHAATNGVVH LIDKVISITIT NNIQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRLGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTELVGCS GDMLTINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAASDVST AIDLFRQAGL
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
 451 HGQTLETGG KKLRFVYRN SLCIENSCIA AHDKRGRYGI LFTMDRVLT
 501 PMGTVMVDLV GDNRFSLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SIQGGKLEVS
 601 LKNNVSVNKK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2003:442069 CAPLUS <LOGINID:20080924>>
 DOCUMENT NUMBER: 139:18315
 TITLE: Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer
 INVENTOR(S): Afar, Daniel; Aziz, Natasha; Ginsburg, Wendy M.; Gish, Kurt C.; Glynn, Richard; Hevezi, Peter A.; Mack, David H.; Murray, Richard; Watson, Susan R.; Wilson, Keith E.; Zlotnik, Albert
 PATENT ASSIGNEE(S): Eos Biotechnology, Inc., USA
 SOURCE: PCT Int. Appl., 1385 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 38
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042661	A2	20030522	WO 2002-KX36810	20021113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
EP 1721977	A2 20061115	EP 2006-7721 20020917
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR	
US 20070042360	A1 20070222	US 2002-245882 20020917
WO 2003042661	A2 20030522	WO 2002-US36810 20021113
WO 2003042661	A3 20041028	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
US 20040197325	A1 20041007	US 2003-741657 20031219
US 7276372	B2 20071002	
US 20070059748	A1 20070315	US 2006-516476 20060906
US 20070154928	A1 20070705	US 2007-625458 20070122

PRIORITY APPLN. INFO.:

US 2001-350666P	P 20011113
US 2001-335394P	P 20011115
US 2001-332464P	P 20011121
US 2001-334393P	P 20011129
US 2001-340376P	P 20011214
US 2002-347211P	P 20020108
US 2002-347349P	P 20020110
US 2002-356714P	P 20020213
US 2002-359077P	P 20020220
US 2002-368809P	P 20020329
US 2002-370110P	P 20020404
US 2002-372246P	P 20020412
US 2002-386614P	P 20020605
US 2002-396839P	P 20020716
US 2002-397775P	P 20020722
US 2002-397845P	P 20020722
US 2002-409450P	P 20020909
WO 2002-US36810	W 20021113
US 2001-299234P	P 20010618
US 2001-315287P	P 20010827
US 2001-323469P	P 20010917
US 2001-323887P	P 20010920
US 2001-325114P	P 20010925
US 2001-340944P	P 20011029
US 2002-355145P	P 20020208
US 2002-355257P	P 20020208
US 2002-369899P	P 20020404
US 2002-173999	A 20020617
EP 2002-766297	A3 20020917
US 2002-245882	A1 20020917
US 2002-435618P	P 20021220

AB Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases, or are otherwise regulated in disease. Mol. profiles of various normal and cancerous

tissues were determined and analyzed using the Affymetrix/Eos Hu3 GeneChip array comprising .apprx.58,680 probesets. Related methods and compns. that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions. [This abstract record is one of twelve records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 537729-48-9

RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer)

RN 537729-48-9 CAPLUS

CN Tumor-associated protein (human clone W003042661-SEQID-C295) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPVNCA
51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA
101 LPLSNLYETL GVGSTTTQL YDRTTEKLRP EMEGPGSFTI FAPSNEAWAS
151 LPAEVLDSL SVNVIELLNA LRYHMVGRRV LTDELKHGMT LTSMYQNSNI
201 QIHHYPNGIV TVNCARLLKA DHHTATNGVVH LIDKVISITIT NNIQIIEIE
251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRLGDP
301 EALRDLNLNH ILKSAMCAEA IVAGLSVETL EGTITLEVGCs GDMLIINGKA
351 IISNKDILAT NGVIHYIDEL LIPDSAKTFL ELAAESDVST ADLDFRQAGL
401 GNHLGSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
451 HGQTLETGG KKLRFVYVRN SLCIENS CIA AHDKRGRYGT LFTMDRVLTP
501 PMGTVMVDLKG GDNRFSLMVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQOGKLEVS
601 LKNNVSVNKG EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:242516 CAPLUS <<LOGINID:20080924>>

DOCUMENT NUMBER: 138:266955

TITLE: Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

INVENTOR(S): James, Robert; Henry, Julianne; Kazenwadel, Jan; Van Host, Pellekaan Nick; MacPherson, Anne; O'Connor, Susan

PATENT ASSIGNEE(S): Medimolecular Pty. Ltd., Australia

SOURCE: PCT Int. Appl., 430 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025214	A1	20030327	WO 2002-AU1258	20020913
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,			

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002325088 A1 20030401 AU 2002-325088 20020913
 AU 2002325088 B2 20070809
 EP 1438427 A1 20040721 EP 2002-757979 20020913
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 US 20050053967 A1 20050310 US 2004-800322 20040312
 AU 2007201611 A1 20070503 AU 2007-201611 20070412
 PRIORITY APPLN. INFO.: US 2001-322288P P 20010914
 AU 2002-325088 A3 20020913
 WO 2002-AU1258 W 20020913

AB The present invention relates generally to novel nucleic acid mols., the levels and/or patterns of expression of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm and to derivs., homologs or analogs of said mols. More particularly, the present invention is directed to novel nucleic acid mols., the levels of expression of which are indicative of the onset and/or progression of a gastrointestinal tract neoplasm, such as an adenoma, and to derivs., homologs or analogs of said mols. The present invention is further directed to isolated proteins encoded thereby and to derivs., homologs, analogs, chemical equivalent and mimetics thereof. The identification of

adenoma

markers and adenoma markers together with identification of their expression uplift levels and expression profile can now be correlated to disease stage and/or cancer invasiveness. The mols. of the present invention are useful in a range of prophylactic, therapeutic, and/or diagnostic applications including, but not limited to, those relating to the diagnosis and/or treatment of colorectal neoplasms such as colorectal adenomas. In a related aspect, the present invention is directed to a method of screening a subject for the onset, predisposition to the onset, and/or progression of a neoplasm by screening for modulation in the level of expression of one or more nucleic acid mol. markers.

IT

503193-38-2
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma)

RN

503193-38-2 CAPLUS

CN

Adenoma-associated protein (human clone 4-11e) (9CI) (CA INDEX NAME)

SEQ

1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA
 101 LPLSNLYETL GVGVSITTQL YDRTTEKLPR EMEGPGSFTI FAPSNEAWAS
 151 LPAEVLDSLVS SNVNIELLNA LRYHMVGRVR LTDELKHGMT LTSMYQNSNI
 201 QIHHPNGIV TVNCARLLKA DHHAATNGVVH LIDKVISIT NIINQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETILNRLGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTITLEVGCs GDMILINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLPRQAGL
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRLNLRNHII KQCLASKYLI
 451 HGQTLETLLG KKLRFVYVRN SLCIENS CIA AHDKRGRYGT LFTMDRVLP
 501 PMGTVMVDVLK GDNRF5MLVA AIQSAGLTFE LNREGVYTVF APTNEAFRAL
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKELEVS
 601 LKNNVSVNKP EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:242452 CAPLUS <<LOGINID:20080924>>
 DOCUMENT NUMBER: 138:282427
 TITLE: Gene expression profiles useful in methods of
 diagnosis of cancer compositions and methods of
 screening for modulators of cancer
 INVENTOR(S): Afar, Daniel; Aziz, Natasha; Gish, Kurt C.; Hevezi,
 Peter A.; Mack, David H.; Wilson, Keith E.; Zlotnik,
 Albert
 PATENT ASSIGNEE(S): EOS Biotechnology, Inc., USA
 SOURCE: PCT Int. Appl., 767 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 38
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025138	A2	20030327	WO 2002-US29560	20020917
WO 2003025138	A3	20030508		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2459219	A1	20030327	CA 2002-2459219	20020917
WO 2003025138	A2	20030327	WO 2002-XA29560	20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003025138	A2	20030327	WO 2002-XB29560	20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003025138	A2	20030327	WO 2002-XC29560	20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	UG,	UZ,	UZ,	VC,	VN,	YU,	ZA,	ZN,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	BG,
		CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,	SE,	SK,	TR,	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,
		NE,	SN,	TD,	TG												
WO	2003025138	A2					20030327					WO 2002-XD29560					20020917
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	UG,	UZ,	UZ,	VC,	VN,	YU,	ZA,	ZN,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	BG,
		CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,	SE,	SK,	TR,	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,
		NE,	SN,	TD,	TG												
WO	2003025138	A2					20030327					WO 2002-XE29560					20020917
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	UG,	UZ,	UZ,	VC,	VN,	YU,	ZA,	ZN,	ZW						
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	BG,
		CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,	SE,	SK,	TR,	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,
		NE,	SN,	TD,	TG												
WO	2003025138	A2					20030327					WO 2002-XF29560					20020917
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,														

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

AU 2002330039 A1 20030401 AU 2002-330039 20020917
EP 1434881 A2 20040707 EP 2002-766297 20020917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
JP 2005518782 T 20050630 JP 2003-529912 20020917
EP 1721977 A2 20061115 EP 2006-7721 20020917
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
LI, LU, MC, NL, PT, SE, SK, TR
US 20070042360 A1 20070222 US 2002-245882 20020917
US 20040197325 A1 20041007 US 2003-741657 20031219
US 7276372 B2 20071002
US 20070059748 A1 20070315 US 2006-516476 20060906
US 20070154928 A1 20070705 US 2007-625458 20070122
PRIORITY APPLN. INFO.: US 2001-323469P P 20010917
US 2001-323887P P 20010920
US 2001-350666P P 20011113
US 2002-355145P P 20020208
US 2002-355257P P 20020208
US 2002-372246P P 20020412
US 2001-299234P P 20010618
US 2001-315287P P 20010827
US 2001-325114P P 20010925
US 2001-340944P P 20011029
US 2002-369899P P 20020404
US 2002-173999 A 20020617
EP 2002-766297 A3 20020917
US 2002-245882 A1 20020917
WO 2002-US29560 W 20020917
US 2002-435618P P 20021220

AB Described herein are genes whose expression are up-regulated or
down-regulated in specific cancers, including acute lymphocytic leukemia,
glioblastoma, glioblastoma multiforme, glioma, kidney cancer, stomach
cancer, melanoma, and benign nevi. Mol. profiles of various normal and
cancerous tissues were determined and analyzed using the Affymetrix/Eos Hu01
and Hu03 GeneChip microarrays containing 35,403 and 59,680 probe sets, resp.
Related methods and compns. that can be used for diagnosis and treatment
of those cancers are disclosed. Also described herein are methods that
can be used to identify modulators of selected cancers. [This abstract
record is one of nine records for this document necessitated by the large
number of index entries required to fully index the document and publication
system constraints.]

IT 503636-40-6
RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU
(Therapeutic use); ANST (Analytical study); BIOL (Biological study);
USES (Uses)
(amino acid sequence; gene expression profiles useful in methods of
diagnosis of cancer compns. and methods of screening for
modulators of cancer)

RN 503636-40-6 CAPLUS
CN Tumor-associated protein (human clone W003025138-SEQID-279) (9CI) (CA
INDEX NAME)

SEQ 1 MALFVRLALL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHPNVCA
51 VQKVIQTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGPAA
101 LPLSNLYETL GVVGSITTQL YTDRTKELRP EMEGPGSFTI FAPSPNEAWAS
151 LPAEVLDSLIV SNVNIELLNA LRYHMVGRVR LTDELKHGMT LTSMYQNSNI
201 QIHHPNGVIV TVNCARLLKA DHHATNGVVH LIDKVISITIT NNIQIIEIE

251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFKIPS ETLNRILGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLVGCs GDMITNGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFRQAGL
 401 GNHLGSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
 451 HGOTLETGG KKLRFVYRN SLCIENS CIA AHDKRGRYGT LFTMDRVLT
 501 PMGTVMVVLK GDNRFMSLVA AIQSAGLTET LNRGVYTVF APTNEAFRAL
 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGGKLEVS
 601 LKNNVSVNKP EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:928019 CAPLUS <<LOGINID:20080924>>
 DOCUMENT NUMBER: 138:1132
 TITLE: Tumor-associated nucleic acids and proteins for
 immunotherapy and diagnosis of colon cancer
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather;
 Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John
 A.; Wang, Tongtong; Jiang, Yuqiu; Smith, Carole L.;
 King, Gordon E.; Wang, Aijun; Clapper, Jonathan D.;
 Skeiky, Yasir A. W.; Fanger, Gary R. C.; Vedvick,
 Thomas S.; Carter, Darrick
 PATENT ASSIGNEE(S): Corixa Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S.
 Ser. No. 922,217.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020182191	A1	20021205	US 2001-25380	20011219
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020076414	A1	20020620	US 2001-922217	20010803
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2002256186	A1	20021028	AU 2002-256186	20020409
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:			US 1998-221298	A2 19981223
			US 1999-347496	A2 19990702
			US 1999-401064	A2 19990922
			US 1999-444252	A2 19991119
			US 1999-454150	B2 19991202
			WO 1999-US30909	W 19991223
			US 1999-476296	B2 19991230
			US 2000-480321	B2 20000110
			US 2000-504629	B2 20000215
			US 2000-519444	B2 20000306
			US 2000-575251	B2 20000519
			US 2000-609448	A2 20000629
			US 2000-649811	A2 20000828
			US 2001-833263	A2 20010410
			US 2001-922217	A2 20010803
			US 1999-444242	A 19991119
			US 2000-444252	A2 20000410
			US 2001-25380	A 20011219
			WO 2002-US11475	W 20020409

AB Comps. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Comps. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such comps. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 476595-10-5P
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence; tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer)

RN 476595-10-5 CAPLUS

CN Colon tumor-associated protein (human clone US20020182191-SEQID-121) (9CI)
 (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQRVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPPAA
 101 LPLSNLYETL GVGSGTTTQL YDTRTEKLRP EMEGPGSFTI FAPSNEAWAS
 151 LPAEVLDSLVS SNVNIELLNA LRYHMVGRVR LTDELKHGMT LTSMYQNSNI
 201 QIHHYPNGIV TVNCAELLKA DHHAATNGVVH LIDKVISITIT NNIQIIEIE
 251 DTFETILRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRIILGDP
 301 EALRDLNNHN ILKSAMCAEA IVAGLSVETL EGTITLEVGCS GDMTLINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAASDVST ADLFRQAGL
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
 451 HGQTLETLGG KKLRFVYVRN SLCIENS CIA AHDKRGRYGT LFTMDRVLTP
 501 PMGTVMVDLKL GDNRFSLMVA AIQSAGLTF LNREGVYTVF APTNEAFRAL
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SIQQDKLEVS
 601 LKNVVSVNKK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:616199 CAPLUS <<LOGINID:20080924>>
 DOCUMENT NUMBER: 137:151147
 TITLE: Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer
 INVENTOR(S): Wang, Aijun; Clapper, Jonathan D.; Stolk, John A.; Meagher, Madeleine Joy
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 649,811.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020110547	A1	20020815	US 2001-833263	20010410
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020076414	A1	20020620	US 2001-922217	20010803
US 20020182191	A1	20021205	US 2001-25380	20011219
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002256186	A1	20021028	AU 2002-256186	20020409
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:				
			US 1998-221298	A2 19981223
			US 1999-347496	A2 19990702
			US 1999-401064	A2 19990922
			US 1999-454150	A2 19991202
			WO 1999-US30909	A2 19991223
			US 1999-476296	A2 19991230
			US 2000-480321	A2 20000110
			US 2000-504629	A2 20000215
			US 2000-519444	A2 20000306
			US 2000-444252	A2 20000410
			US 2000-575251	A2 20000519
			US 2000-609448	A2 20000629
			US 2000-649811	A2 20000828
			US 1999-444242	A 19991119

US 1999-444252 A2 19991119
US 2001-833263 A2 20010410
US 2001-922217 A2 20010803
US 2001-25380 A 20011219
WO 2002-US11475 W 20020409

AB Comps. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Comps. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such comps. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 444969-60-2P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer)

RN 444969-60-2 CAPLUS

CN Colon tumor-associated protein (human clone US20020110547-SEQID-121) (9CI)
(CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA
101 LPLSNLYETL GVGSTTTQL YDRTTEKLRP EMEGPGSFTI FAPSNEAWAS
151 LPAEVLDSL SVNVIELLNA LRYHVMGRRV LTDELKHGMT LTSMYQNSNI
201 QIHHPNGIV TVNCARLLKA DHHTATNGVVH LIDKVISITIT NNIQIIEIE
251 DTFETIRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRLGDP
301 EALRDLNLNH ILKSAMCAEA IVAGLSVETL EGTILEVGCS GDMILINGKA
351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFRQAGL
401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
451 HGQTLETLLG KKLRFVYVRN SLCIENS CIA AHDKRGRYGT LFTMDRVLT
501 PMGTVMVDLV GDNRFMSLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGEKLEVS
601 LKNVVSUNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:466537 CAPLUS <<LOGINID:20080924>>

DOCUMENT NUMBER: 137:42650

TITLE: Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John A.; Wang, Tongtong; Jiang, Yuqiu; Smith, Carole L.; King, Gordon E.; Wang, Aijun; Clapper, Jonathan D.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 50 pp., Cont.--in-part of U.S. Ser. No. 833,263.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020076414	A1	20020620	US 2001-922217	20010803
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020182191	A1	20021205	US 2001-25380	20011219
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002256186	A1	20021028	AU 2002-256186	20020409
US 20050260177	A1	20051124	US 2005-108172	20050415

PRIORITY APPLN. INFO.:

US 1998-221298	A2	19981223
US 1999-347496	A2	19990702
US 1999-401064	A2	19990922
US 1999-454150	B2	19991202
WO 1999-US30909	W	19991223
US 1999-476296	A2	19991230
US 2000-480321	B2	20000110
US 2000-504629	A2	20000215
US 2000-519444	A2	20000306
US 2000-444252	A2	20000410
US 2000-575251	A2	20000519
US 2000-609448	A2	20000629
US 2000-649811	A2	20000828
US 2001-833263	A2	20010410
US 1999-444242	A	19991119
US 1999-444252	A2	19991119
US 2001-922217	A2	20010803
US 2001-25380	A	20011219
WO 2002-US11475	W	20020409

AB Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Thus, colon tumor-associated proteins are isolated by PCR-based subtraction and microarray anal., use of SCID mouse antisera, and conventional subtraction. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as

colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 438430-54-7P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer)

RN 438430-54-7 CAPLUS

CN Colon tumor-associated protein (human clone US20020076414-SEQID-121) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLLLAL ALALALGPAA TLAGPAKSPFY QLVLQHSRLR GRQHGFNVCA

51 VQKVGITNRK YFTNCKQWYQ RKICGKSTIVI SYECCPGSYEK VPGEKGCPPAA

101 LPLSNLYETL GVGSGTITTL YDRTTEKLRP EMEGPGSFTI FAPSNEAWAS

151 LPAEVLDSL SNVNIELLNA LRYHMGRRV LTDELKHGMT LTSMYQNSNI

201 QIHHPNGIV TVNCARLLKA DHHTANGVVH LIDKVISITIT NNIQIIEIE

251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRIILGDP

301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTILEVGCS GDMLTINGKA

351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFRQAGL

401 GNLHSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY

451 HGQTLETLLG KKLRFVYVRN SLCIENSCIA AHDKRGYGT LFTMDRVLTP

501 PMGTVMVLK GDNRFMSLVA AIQSAGLTIET LNREGVYTVF APTNEAFRAL

551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRK SLQGDKLEVS

601 LKNNVSVNKP EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA

651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L17 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:507728 CAPLUS <<LOGINID:20080924>>

DOCUMENT NUMBER: 135:121178

TITLE: Identification of colon cancer-associated proteins for immunotherapy and diagnosis

INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John A.; King, Gordon E.; Wang, Tongtong; Jiang, Yuqiu

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 472 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049716	A2	20010712	WO 2000-US35596	20001229
WO 2001049716	A3	20020131		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,			

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2396036 A1 20010712 CA 2000-2396036 20001229
 EP 1242598 A2 20020925 EP 2000-989592 20001229

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 1999-476296 A 19991230
 US 2000-480321 A 20000110
 US 2000-504629 A 20000215
 US 2000-519444 A 20000306
 US 2000-575251 A 20000519
 US 2000-609448 A 20000629
 US 2000-649811 A 20000828
 WO 2000-US35596 W 20001229

AB The authors disclose the use of a cDNA library and subtractive PCR to identify a number of genes, and their proteins, which are overexpressed in human colon tumors. In addition, soluble tumor proteins expressed in serum of colon tumor-bearing SCID mice were used to generate polyclonal antibodies for probing a cDNA expression library.

IT 148710-76-3, Protein (human clone β ig-h3 transforming growth factor β -induced precursor reduced)
 RL: ANT (Analyte); ARG (Analytical reagent use); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (amino acid sequence; identification and immunogenicity of human colon tumor-associated antigens)

RN 148710-76-3 CAPLUS

CN Protein (human clone β ig-h3 transforming growth factor β -induced precursor reduced) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLALL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVGITNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCFAA
 101 LPLSNLYETL GUVGSTTTQL YTDRTKLRP EMEGPGSFIT FAPSNEAWAS
 151 LPAEVLDSL V SNVNIELLNA LRYHVMGRRV LTDELKHGMT LTSMYQNSNI
 201 QIHHYPNGIV TVNCARLLKA DHHATNGVVH LIDKVISIT NNIQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFERIPS ETLNRIILGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLLEVGS DMGLTINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAASDVST AIDLFRAQL
 401 GNHLSGSERL TLLAPLNSVF KDGTTPPIDAH TRNLLRNHII KDQLASKYLY
 451 HGQTLETLLG KKLRFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTLP
 501 PMGTVMVLK GDNRFMSLVA AIQSAGLTET LNRGVYITVF APTNEAFRAL
 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS
 601 LKNVNVSVNK EPVAEPDIMA TNGVVHVIIT VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	91.93	193.62
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-8.80	-9.60

FILE 'STNGUIDE' ENTERED AT 15:03:50 ON 24 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 19, 2008 (20080919/UP).

=> d his

(FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008

FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008

L1 125 S [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNLK][YN]H[MIG][VLQG][GKTD] [

FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008

L2 78 S L1

L3 26 S L1/THU

FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008

L4 0 S L1 AND SQL<30

FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008

L5 1 S US20070004622/PN

L6 ANALYZE L5 1 RN : 10 TERMS

FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008

L7 10 S L6

L8 10 S L6

L9 10 S L1 AND L8

FILE 'CAPLUS' ENTERED AT 14:53:35 ON 24 SEP 2008

L10 297112 S TUMOR OR TUMOUR

L11 45619 S ONCO?

L12 525362 S NEOPLASM

L13 246205 S CANCER

L14 223599 S CARCINO?

L15 782082 S L10-L14

L16 16 S L3 (L) L15

L17 17 S L16 OR L5

FILE 'STNGUIDE' ENTERED AT 14:55:58 ON 24 SEP 2008

FILE 'CAPLUS' ENTERED AT 15:02:52 ON 24 SEP 2008

FILE 'STNGUIDE' ENTERED AT 15:03:50 ON 24 SEP 2008

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.54

194.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-9.60

FILE 'CAPLUS' ENTERED AT 15:09:15 ON 24 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13
FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> fil stng		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.48	194.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-9.60

FILE 'STNGUIDE' ENTERED AT 15:09:32 ON 24 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 19, 2008 (20080919/UP).

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	194.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-9.60

FILE 'CAPLUS' ENTERED AT 15:10:07 ON 24 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 24 Sep 2008 VOL 149 ISS 13
FILE LAST UPDATED: 23 Sep 2008 (20080923/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> help role

CAS roles are CAS indexing terms consisting of codes that describe the new or novel information reported about a substance or a class of compounds. Specific roles have 3-letter codes. Super roles have 4-letter codes. Super roles are automatically generated from the specific roles, and are upposted for searching. The PREP (Preparation) role is available for documents from 1907 to the present. Other roles are available for all indexed documents from 1967 to the present.

To search a role for a specific substance, append the CAS Registry Number or a Registry File L-number answer set with a slash and the code for the role, e.g., 67-68-5/THU. To search more than one role, separate a list of roles by commas and no spaces, e.g., 67-68-5/THU,ADV. Only one role may be appended to an L-number answer set. Use the OR operator to apply multiple roles to an L-number, e.g., S L1/THU OR L1/ADV.

To search roles assigned to index headings for classes of compounds, follow the heading with a slash and the role or roles separated by commas, e.g., PHENOLS/POL,REM.

Roles are displayed in the RL (Role) field within the IT (Index Term) field. Roles are included in any display format that contains the IT or RL field. Enter SET ROLES OFF at an arrow prompt (=>) to suppress display of codes and text for roles. Enter SET ROLES CODES to display only codes. Enter SET ROLES TEXT to return to default display (codes and names). Enter HELP SET ROLES at an arrow prompt for more information.

Enter HELP THESAURUS and HELP RCODE at an arrow prompt in this file for information on using the role thesaurus to find role definitions and narrower and broader terms.

The following is a hierarchical list of CAS roles. Under each super role are listed the specific roles that generate the super role.

List of CAS Roles (1)

ANST Analytical Study

ANT Analyte

AMX Analytical Matrix

ARG Analytical Reagent Use

ARU Analytical Role, Unclassified

BIOL Biological Study

ADV Adverse Effect, Including Toxicity

AGR Agricultural Use

BAC Biological Activity or Effector, Except Adverse (2)

BCP Biochemical Process (3)

BMF Bioindustrial Manufacture

BOC Biological Occurrence (2)

BPN Biosynthetic Preparation

BPR Biological Process (2)

BSU Biological Study, Unclassified

BUU Biological Use, Unclassified

COS Cosmetic Use (3)

DGN Diagnostic Use (3)

DMA Drug Mechanism of Action (3)

FFD Food or Feed Use

MFM Metabolic Formation (2)

NPO Natural Product Occurrence (3)

PAC Pharmacological Activity (3)

PKT Pharmacokinetics (3)

THU Therapeutic Use

CMBI Combinatorial Study (3)

CPN Combinatorial Preparation (3)

CRT Combinatorial Reactant (3)

CRG Combinatorial Reagent (3)

CST Combinatorial Study (3)

CUS Combinatorial Use (3)

FORM Formation, Nonpreparative

FMU Formation, Unclassified

GFM Geological or Astronomical Formation

MFM Metabolic Formation (2)

OCCU Occurrence

BOC Biological Occurrence (2)

GOC Geological or Astronomical Occurrence

NPO Natural Product Occurrence (3)

OCU Occurrence, Unclassified

POL Pollutant

PREP Preparation (4)

BMF Bioindustrial Manufacture

BPN Biosynthetic Preparation

BYP Byproduct

CPN Combinatorial Preparation (3)

IMF Industrial Manufacture

PUR Purification or Recovery

PNU Preparation, Unclassified (5)

SPN Synthetic Preparation

PROC Process

BCP Biochemical Process (3)

BPR Biological Process (2)

GPR Geological or Astronomical Process
 PEP Physical, Engineering, or Chemical Process
 CPS Chemical Process (6)
 EPR Engineering Process (6)
 PYP Physical Process (6)
 REM Removal or Disposal

PRPH Prophetic Substance (7)

RACT Reactant or Reagent (2,6)

RCT Reactant (8)
 CRT Combinatorial Reactant (3)
 RGT Reagent (3)
 CRG Combinatorial Reagent (3)

USES Uses

AGR Agricultural Use
 ARG Analytical Reagent Use
 BUU Biological Use, Unclassified
 CAT Catalyst Use
 COS Cosmetic Use (3)
 CUS Combinatorial Use (3)
 DGN Diagnostic Use (3)
 FFD Food or Feed Use
 MOA Modifier or Additive Use
 NUU Other Use, Unclassified (9)
 POF Polymer in Formulation
 TEM Technical or Engineered Material Use
 THU Therapeutic Use

Specific roles that are not upposted to any super roles:

MSC Miscellaneous
 PRP Properties

- (1) Super roles have 4-letter codes. Specific roles have 3-letter codes. Under each super role are listed the corresponding specific roles that are retrieved when you search that super role.
- (2) Used from CA Vol. 66 (1967) to Vol. 135 (2001)
- (3) Used starting with CA Vol. 136 (2002)
- (4) The PREP super role has been added to records back to 1907.
- (5) Used from CA vol. 66 (1967) to vol. 145 (2006).
- (6) Used from CA vol. 136 (2002) to CA vol. 145 (2006).
- (7) Used starting with records from CA vol. 148 (2008).
- (8) Searching the RCT (Reactant) role retrieves references from CA Vol. 66 (1967) to the present. Searching the RACT (Reactant or Reagent) super role retrieves references with the CRT, CRG, RGT, or RCT references starting with CA Vol. 136 (2002).
- (9) Starting with CA Vol. 136 (2002), the searchable text for the NUU role changed from NONBIOLOGICAL USE, UNCLASSIFIED/RL to OTHER USE, UNCLASSIFIED/RL. Search the code NUU/RL to retrieve records from CA Vol. 66 (1967) to the present.

=> d his

{FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008}

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008

L1 FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008
 125 S [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNLK][YN]H[MIG][VLQG][GKTD][

L2 FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008
 78 S L1

L3 26 S L1/THU

L4 FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008
 0 S L1 AND SQL<30

L5 FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008
 1 S US20070004622/PN

L6 ANALYZE L5 1 RN : 10 TERMS

L7 FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008
 10 S L6

L8 10 S L6

L9 10 S L1 AND L8

L10 FILE 'CAPLUS' ENTERED AT 14:53:35 ON 24 SEP 2008
 297112 S TUMOR OR TUMOUR

L11 45619 S ONCO?

L12 525362 S NEOPLASM

L13 246205 S CANCER

L14 223599 S CARCINO?

L15 782082 S L10-L14

L16 16 S L3 (L) L15

L17 17 S L16 OR L5

FILE 'STNGUIDE' ENTERED AT 14:55:58 ON 24 SEP 2008

FILE 'CAPLUS' ENTERED AT 15:02:52 ON 24 SEP 2008

FILE 'STNGUIDE' ENTERED AT 15:03:50 ON 24 SEP 2008

FILE 'CAPLUS' ENTERED AT 15:09:15 ON 24 SEP 2008

FILE 'STNGUIDE' ENTERED AT 15:09:32 ON 24 SEP 2008

FILE 'CAPLUS' ENTERED AT 15:10:07 ON 24 SEP 2008

=> d ti l3 1-26

L3 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

TI Use of β ig-h3 protein comprising fas-1 domains, EMI domain and RGD motifs for treatment and prevention of angiogenesis-related disorders

L3 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

TI Prevention and treatment of inflammation by inhibiting FEX-2-dependent adhesion of lymphocytes to the endothelium

L3 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

TI Differentially expressed nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

L3 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

TI Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening

L3 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

L3 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI TAT (Tumor-associated Antigenic Target) polypeptides and methods for diagnosis and treatment of tumors of glial origin

L3 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer

L3 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L3 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases

L3 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L3 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Nucleic acid and encoded protein sequences that are differentially expressed in psoriatic skin and their use for diagnosis and treatment of psoriasis

L3 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Human protein and cDNA sequences for diagnostics and therapeutics

L3 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Methods of testing for bronchial asthma or chronic obstructive pulmonary disease, and drug screening for the same, using identified differentially expressed IL-13-stimulated marker genes

L3 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Genetic and protein manipulation of β ig-H3 for the treatment and cure of muscular dystrophies

L3 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L3 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L3 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L3 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L3 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L3 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses

L3 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Protein-protein interactions in human adipocyte cells and method for selecting modulators of these interactions

L3 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L3 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L3 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Nucleic acids and their encoded polypeptides from human tissues

L3 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Identification of colon cancer-associated proteins for immunotherapy and diagnosis

L3 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer

=> d his

(FILE 'HOME' ENTERED AT 14:46:31 ON 24 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:48:53 ON 24 SEP 2008

FILE 'REGISTRY' ENTERED AT 14:50:57 ON 24 SEP 2008
 L1 125 S [IDEK][EAQ]L[LRA][NDS][ALKI][LY][RNLK][YN]H[MIG][VLQG][GKTD] [

FILE 'CAPLUS' ENTERED AT 14:51:08 ON 24 SEP 2008
 L2 78 S L1
 L3 26 S L1/THU

FILE 'REGISTRY' ENTERED AT 14:51:35 ON 24 SEP 2008
 L4 0 S L1 AND SQL<30

FILE 'CAPLUS' ENTERED AT 14:52:33 ON 24 SEP 2008
 L5 1 S US20070004622/PN
 L6 ANALYZE L5 1 RN : 10 TERMS

FILE 'REGISTRY' ENTERED AT 14:52:50 ON 24 SEP 2008
 L7 10 S L6
 L8 10 S L6
 L9 10 S L1 AND L8

FILE 'CAPLUS' ENTERED AT 14:53:35 ON 24 SEP 2008
 L10 297112 S TUMOR OR TUMOUR
 L11 45619 S ONCO?
 L12 525362 S NEOPLASM
 L13 246205 S CANCER
 L14 223599 S CARCINO?
 L15 782082 S L10-L14

L16 16 S L3 (L) L15
L17 17 S L16 OR L5

FILE 'STNGUIDE' ENTERED AT 14:55:58 ON 24 SEP 2008

FILE 'CAPLUS' ENTERED AT 15:02:52 ON 24 SEP 2008

FILE 'STNGUIDE' ENTERED AT 15:03:50 ON 24 SEP 2008

FILE 'CAPLUS' ENTERED AT 15:09:15 ON 24 SEP 2008

FILE 'STNGUIDE' ENTERED AT 15:09:32 ON 24 SEP 2008

FILE 'CAPLUS' ENTERED AT 15:10:07 ON 24 SEP 2008

=> s l3 or l5

L18 27 L3 OR L5

=> d ti 1-27

L18 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Use of β ig-h3 protein comprising fas-1 domains, EMI domain and RGD motifs for treatment and prevention of angiogenesis-related disorders

L18 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Prevention and treatment of inflammation by inhibiting FEX-2-dependent adhesion of lymphocytes to the endothelium

L18 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Differentially expressed nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

L18 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening

L18 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

L18 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI TAT (Tumor-associated Antigenic Target) polypeptides and methods for diagnosis and treatment of tumors of glial origin

L18 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Use of a peptide that interacts with α v β 3 integrin of endothelial cell

L18 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer

L18 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L18 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases

L18 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L18 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Nucleic acid and encoded protein sequences that are differentially expressed in psoriatic skin and their use for diagnosis and treatment of psoriasis

L18 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Human protein and cDNA sequences for diagnostics and therapeutics

L18 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Methods of testing for bronchial asthma or chronic obstructive pulmonary disease, and drug screening for the same, using identified differentially expressed IL-13-stimulated marker genes

L18 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Genetic and protein manipulation of β ig-H3 for the treatment and cure of muscular dystrophies

L18 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L18 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L18 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L18 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L18 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L18 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses

L18 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Protein-protein interactions in human adipocyte cells and method for selecting modulators of these interactions

L18 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L18 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L18 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Nucleic acids and their encoded polypeptides from human tissues

L18 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

TI Identification of colon cancer-associated proteins for immunotherapy and

diagnosis

L18 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
TI Colon tumor-specific nucleic acids and proteins and their use for
immunotherapy and diagnosis of colon cancer

=> d ibib abs 1

L18 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:788610 CAPLUS <<LOGINID:20080924>>
DOCUMENT NUMBER: 147:158465
TITLE: Use of Big-h3 protein comprising fas-l domains,
EMI domain and RGD motifs for treatment and prevention
of angiogenesis-related disorders
INVENTOR(S): Nam, Ju-Ock; Kim, Jung-Eun; Jeong, Ha-Won; Lee,
Sung-Jin; Lee, Byung-Heon; Choi, Je-Yong; Park,
Rang-Woon; Park, Jae-Yong; Kim, In-San; Son, Hye-Nam
PATENT ASSIGNEE(S): Kyungpook National University Industry-Academic
Cooperation Foundation, S. Korea
SOURCE: U.S. Pat. Appl. Publ., 83pp., Cont.-in-part of U.S.
Ser. No. 578,463.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070167369	A1	20070719	US 2007-712460	20070301
WO 2005099743	A1	20051027	WO 2004-KR851	20040413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			WO 2004-KR851	W 20040413
			US 2006-578463	A2 20061013

AB The present invention relates to the novel use of cell adhesion mol.
Big-h3 comprising EMI domain, four fas-l domains and RGD protein
motifs. More particularly, the invention relates to a method for the
inhibition of the adhesion, migration and/or proliferation of endothelial
cells, and/or for the inhibition of angiogenesis, using cell adhesion mol.
Big-h3, or functional equivalent thereof. Furthermore, the invention
provides a method for treating or preventing angiogenesis-related
diseases, using the polypeptides.

=> d hitseq 1

L18 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
IT 943948-05-8 943948-06-9 943948-07-0
943948-08-1
RL: BSU (Biological study, unclassified); PRP (Properties); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
 (amino acid sequence; use of β ig-h3 protein comprising fas-1
 domains, EM1 domain and RGD motifs for treatment and prevention of
 angiogenesis-related disorders)

RN 943948-05-8 CAPLUS

CN Cell adhesion molecule β ig-h3 (TGF- β -induced gene h3) (human EM1
 and Fas1 and RGD domains) (CA INDEX NAME)

SEQ 1 WYQRKICGKS TVISYECCPG YEKVPGEKGC PAALPLSNLY ETLGVGVGSTT
 51 TQLYTDRTTEK LRPEMEGPGS FTIFAPSNEA WASLPAEVL D SLVSNVNIEL
 101 LNALRYHVMV RRVLTDELKH GMTLTSYQN SNIQIHHPN GIVTVNCARL
 151 LKADHHTATNG VVHLIDKVIS TITNNIQII EIEDTFETLR AAVAASGLNT
 201 MLEGNQYTL LAPTNEAFEK IPSETLNRIL GDPEALRDLL NNHILKSAMC
 251 AEAIVAGLSL ETLEGTTLLEV GCSGDMLTIN GKAIISNKDI LATNGVIHYI
 301 DELLIPDSAK TLFELAAESD VSTAIDLFRQ AGLGNHLSGS ERLTLPLAPN
 351 SVFKDGTPII DAHTRNLLRN HIIKDLQASK YLYHGQTLT LGGKKLRV FV
 401 YRNSLCIENS CIAAHDKRGR YGTLFTMDRV LTPPMGTVM D VLKGNDRFMS
 451 LVAAIQSAGL TETLNREGVY TVFAPTNEAF RALPPRERSR LLGDAKELAN
 501 ILKYHIGDEI LVSGGIGALV RLKSLQGD KL EVSLKNNVVS VNKEPVAEPD
 551 IMATNGVVHV ITNVLQPPAN RPQERGD ELSAILEI

RN 943948-06-9 CAPLUS

CN Cell adhesion molecule β ig-h3 (TGF- β -induced gene h3) (Sus
 scrofa EM1 and Fas1 and RGD domains) (CA INDEX NAME)

SEQ 1 WYQRKICGKS TVISYECCPG YEKVPGEKGC PAVLPLSNLY ETLGVGVGSTT
 51 TQLYTDRTTEK LRPEMEGPGS FTIFAPSNEA WASLPAEVL D SLVSNVNIEL
 101 LNALRYHMDV RRVLTDELKH GMALTSYQN SNIQIHHPN GIVTVNCARL
 151 LKADHHTATNG VVHLIDKVIS TVTNNIQII EIEDTFETLR AAVAASGLNT
 201 LLEGDGQYTL LAPSNEAFEK IPAETLNRIL GDPEALRDLL NNHILKSAMC
 251 AEAIVAGLSL ETLEGTTLLEV GCSGDMLTIN GKPIISNKDV LATNGVIHFI
 301 DELLIPDSAK TLFELAAESD VSTAIDLFRQ AGLGSHLSGN ERLTLPLAPN
 351 SVFKDGTPII DARTKNLLN HMIKDLQASK YLYHGQTL D LGGKKLRV FV
 401 YRNSLCIENS CIAAHDKRGR YGTLFTMDRM LTPPMGTVM D VLKGNDRFMS
 451 LVAAIQSAGL TETLNREGVY TVFAPTNEAF QALPLGERNK LLGNAKELAN
 501 ILKYHVHDEI LVSGGIGALV RLKSLQGD KL EVSSKNSLVT VNKEPVAEAD
 551 IMATNGVVHT INTVLRPAN RPQERGD ELSAILEI

RN 943948-07-0 CAPLUS

CN Cell adhesion molecule β ig-h3 (TGF- β -induced gene h3)
 (Oryctolagus cuniculus EM1 and Fas1 and RGD domains) (CA INDEX NAME)

SEQ 1 WYQRKICGKS TVISYECCPG YEKVPGERS C PAALPLANLY ETLGVGVGSTT
 51 TQLYTDRTTEK LRPEMEGPGR FTIFAPSNEA WASLPAEVL D SLVSNVNIEL
 101 LNALRYHMDV RRVLTDELKH GMALTSYQN SKFQIHHPN GIVTVNCARL
 151 LKADHHTATNG VVHLIDKVIS TVTNNIQII EIEDTFETLR AAVAASGLNT
 201 LLES DGQFTL LAPTNEAKEK IPTETLNRIL GDPEALRDLL NNHILKSAMC
 251 AEAIVAGLSM ETLEATTLEV GCSGDMLTIN GKAIISNKDV LATNGVIHFI
 301 DELLIPDSAK TSELAAAGSD VSTAIDLFGQ AGLGTHLSGN ERLTLPLAPN
 351 SVFEEGAPPI DAHTRNLLRN HIIKDLQASK YLYHGQTL D LGGKKLRV FV
 401 YRNSLCIENS CIAAHDKRGR YGTLFTMDRM LTPPSGTVM D VLKGNDRFMS
 451 LVAAIQFRRL TETLNREGAY TVFAPTNEAF QALPPGELNK LLGNAKELAN
 501 ILKYHVGEI LVSGGIGTLV RLKSLQGD KL EVSSKNNAVS VNKEPVAESD
 551 IMATNGVVYA ITSVLQPPAN RPQERGD ELSAILEI

RN 943948-08-1 CAPLUS
 CN Cell adhesion molecule β ig-h3 (TGF- β -induced gene h3) (Mus
 musculus EMI and FasI and RGD domains) (CA INDEX NAME)

SEQ 1 WYQRKICGKS TVISYECCPG YEKVPGEKGC PAALPLSNLY ETMGVVGSTT
 51 TQLYTDRTK LRPMEGPGS FTIFAPSNEA WSSLPAEVL D SLVSNVNI
 101 LNALRIHMD RRVLTDELKH GMTLTSMYQN SNIQIHHPN GIVTVNCARL
 151 LKADHHATNG VVHLIDKVIS TITNNIQQII EIEDTFETLR AAVAASGLNT
 201 VLEGGDQFTL LAPTNEAFEK IPAETLNRI L GDPEALRDLL NNHILKSAMC
 251 AEAIVAGMSM ETLGGTTLEV GCSGDKLTIN GKAVISNKDI LATNGVIHFI
 301 DELLIPDSAK TLLELAGESD VSTAIDILKQ AGLDTHLSGK EQLTFLAPLN
 351 SVFKDGVPRI DAQMKTL LN HMVKEQLASK YLYSGQTLD T LGGKKLRV FV
 401 YRNSLCIENS CIAAHDKRGR FGILFTMDRM LTPPMGTVM D VLKGDNRFSM
 451 LVAAIQSAGL MEILNREGVY TVFAPTNEAF QAMPPEELNK LLANAKELTN
 501 ILKYHIGDEI LVSGGIGALV RLKSLQGDKL EVSSKNNVVS VNKEPVAETD
 551 IMATNGVVYA INTVLQPPAN RPQERGDELA DSALEI

=> fil stng
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 30.23 224.93
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
 ENTRY SESSION
 CA SUBSCRIBER PRICE -0.80 -10.40

FILE 'STNGUIDE' ENTERED AT 15:13:52 ON 24 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Sep 19, 2008 (20080919/UP).

=> log h
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 0.66 225.59
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
 ENTRY SESSION
 CA SUBSCRIBER PRICE 0.00 -10.40

SESSION WILL BE HELD FOR 120 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 15:20:32 ON 24 SEP 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACXB1654

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	12	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	17	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	18	JUL 28	EPFULL enhanced with additional legal status information from the EPOline Register
NEWS	19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	20	JUL 28	STN Viewer performance improved
NEWS	21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	22	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	24	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	25	AUG 25	CA/CAPLUS, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS	26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	27	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	28	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	29	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	30	SEP 29	IFICLS enhanced with new super search field
NEWS	31	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	32	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents

L3 58 DQLASKYLYHGQTLETLG/SQSP

=> s kelanilkyhigdeilvs/sqsp

L4 68 KELANILKYHIGDEILVS/SQSP

=> d his

(FILE 'HOME' ENTERED AT 14:15:35 ON 02 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:23:09 ON 02 OCT 2008

L1 67 S IELLNALRYHMGVRRVLT/SQSP

L2 84 S EALRDLLNNHILKSAMCA/SQSP

L3 58 S DQLASKYLYHGQTLETLG/SQSP

L4 68 S KELANILKYHIGDEILVS/SQSP

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

122.06

124.79

FILE 'CAPLUS' ENTERED AT 14:23:34 ON 02 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14

FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> s l1

L5 68 L1

=> s l2

L6 68 L2

=> s l3

L7 58 L3

=> s l4

L8 58 L4

```
=> fil styng
'STYNG' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'CAPLUS'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
```

```
=> fil stng
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                0.48      125.27
```

```
FILE 'STNGUIDE' ENTERED AT 14:24:26 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 26, 2008 (20080926/UP).
```

```
=> d his
```

```
(FILE 'HOME' ENTERED AT 14:15:35 ON 02 OCT 2008)
```

```
FILE 'REGISTRY' ENTERED AT 14:23:09 ON 02 OCT 2008
```

```
L1      67 S IELLNALRYHMGVRRVLT/SQSP
L2      84 S EALRDLNNHILKSAMCA/SQSP
L3      58 S DQLASKYLYHGQTLTGLG/SQSP
L4      68 S KELANILKYHIGDEILVS/SQSP
```

```
FILE 'CAPLUS' ENTERED AT 14:23:34 ON 02 OCT 2008
```

```
L5      68 S L1
L6      68 S L2
L7      58 S L3
L8      58 S L4
```

```
FILE 'STNGUIDE' ENTERED AT 14:24:26 ON 02 OCT 2008
```

```
=> s cancer
L9      5 CANCER
```

```
=> fil caplus
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                0.12      125.39
```

```
FILE 'CAPLUS' ENTERED AT 14:25:26 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14
FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

```
=> s cancer
L10      246905 CANCER/OBI

=> s carcinoma
L11      155786 CARCINOMA/OBI

=> s onco?
L12      45688 ONCO?/OBI

=> s neoplas?
L13      546919 NEOPLAS?/OBI

=> s tumor or tumour
L14      297654 TUMOR/OBI OR TUMOUR/OBI

=> s angiogen?
L15      40146 ANGIOGEN?/OBI

=> s arterioscler?
L16      11213 ARTERIOSCLER?/OBI

=> s sclerosis
L17      25778 SCLEROSIS/OBI

=> s neovascular glaucoma
L18      52 NEOVASCULAR GLAUCOMA/OBI

=> s diabetic retinopathy
L19      5164 DIABETIC RETINOPATHY/OBI

=> s pterygium
L20      227 PTERYGIUM/OBI

=> s retinal degeneration
L21      1185 RETINAL DEGENERATION/OBI

=> s retrolental fibroplasia
L22      617 RETROLENTAL FIBROPLASIA/OBI

=> s granular conjunctivitis
L23      1 GRANULAR CONJUNCTIVITIS/OBI

=> s rheumatoid arthritis
L24      26118 RHEUMATOID ARTHRITIS/OBI

=> s lupus
L25      17699 LUPUS/OBI
```

=> s thyroid?
L26 71761 THYROID?/OBI

=> s psoriasis
L27 15306 PSORIASIS/OBI

=> s pyogenic granuloma
L28 28 PYOGENIC GRANULOMA/OBI

=> s seborrheic dermatitis
L29 158 SEBORRHEIC DERMATITIS/OBI

=> s acne
L30 7117 ACNE/OBI

=> d his

(FILE 'HOME' ENTERED AT 14:15:35 ON 02 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:23:09 ON 02 OCT 2008

L1 67 S IELLNALRYHVMGRRVLT/SQSP
L2 84 S EALRDLNNHILKSAMCA/SQSP
L3 58 S DQLASKYLYHGQTLTLG/SQSP
L4 68 S KELANILKYHIGDEILVS/SQSP

FILE 'CAPLUS' ENTERED AT 14:23:34 ON 02 OCT 2008

L5 68 S L1
L6 68 S L2
L7 58 S L3
L8 58 S L4

FILE 'STNGUIDE' ENTERED AT 14:24:26 ON 02 OCT 2008

L9 5 S CANCER

FILE 'CAPLUS' ENTERED AT 14:25:26 ON 02 OCT 2008

L10 246905 S CANCER
L11 155786 S CARCINOMA
L12 45688 S ONCO?
L13 546919 S NEOPLAS?
L14 297654 S TUMOR OR TUMOUR
L15 40146 S ANGIOGEN?
L16 11213 S ARTERIOSCLER?
L17 25778 S SCLEROSIS
L18 52 S NEOVASCULAR GLAUCOMA
L19 5164 S DIABETIC RETINOPATHY
L20 227 S PTERYGIUM
L21 1185 S RETINAL DEGENERATION
L22 617 S RETROLENTAL FIBROPLASIA
L23 1 S GRANULAR CONJUNCTIVITIS
L24 26118 S RHEUMATOID ARTHRITIS
L25 17699 S LUPUS
L26 71761 S THYROID?
L27 15306 S PSORIASIS
L28 28 S PYOGENIC GRANULOMA
L29 158 S SEBORRHEIC DERMATITIS
L30 7117 S ACNE

=> s 110-130

L31 914566 (L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR
L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR

L28 OR L29 OR L30)

=> s 15-18

L32 78 (L5 OR L6 OR L7 OR L8)

=> s 132(1)131

L33 31 L32(L)L31

=> s 133 and (pd<20030402 or ad<20030402 or prd<20030402)

L34 20 L33 AND (PD<20030402 OR AD<20030402 OR PRD<20030402)

=> d ti 1-20

L34 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening

L34 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

L34 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer

L34 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Method for detecting presence of colorectal cancer using TIMP1

L34 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

L34 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Immunostimulatory cytokine or encoding nucleic acid in combination with antigen presenting cells for treating cancer, metastasis and infection

L34 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

L34 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Nucleic acid and encoded protein sequences that are differentially expressed in psoriatic skin and their use for diagnosis and treatment of psoriasis

L34 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Genes showing altered patterns of expression in multiple sclerosis and their diagnostic and therapeutic uses

L34 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L34 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Differentially expressed genes for identification, assessment, prevention, and therapy of colon cancer

L34 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

TI Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

L34 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma

L34 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Gene expression profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

L34 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L34 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Colon tumor proteins, antibodies and oligonucleotides for immunotherapy and diagnosis of colon cancer

L34 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer

L34 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer

L34 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Identification of colon cancer-associated proteins for immunotherapy and diagnosis

L34 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 TI Colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer

=> d ibib abs hitseq 1-20

L34 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:429532 CAPLUS <<LOGINID:20081002>>
 DOCUMENT NUMBER: 142:477160
 TITLE: Expression profile of colon cancer specific genes and their use as biomarkers for diagnosis, therapy and drug screening
 INVENTOR(S): Burgess, Christopher; Myerow, Susan; Thiagalingam, Arunthathi; Maimonis, Peter; Molino, Gary; Burgart, Lawrence; Boardman, Lisa Allyn; Thibodeau, Stephen; Lewis, Marcia
 PATENT ASSIGNEE(S): Bayer Healthcare LLC, USA; Mayo Foundation for Medical Education and Research
 SOURCE: PCT Int. Appl., 256 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044990	A2	20050519	WO 2004-US36404	20041101
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

US 20060188889	A1	20060824	US 2003-700439	20031104
US 20080233585	A1	20080925	US 2008-47358	20080313
US 20080194043	A1	20080814	US 2008-52760	20080321 <--

PRIORITY APPLN. INFO.:

	US 2003-700439	A	20031104
	US 2002-433554P	P	20021213 <--
	US 2003-491397P	P	20030731
	US 2003-734564	A1	20031212

AB The present invention relates to novel marker sequences that are differentially expressed in cancer cells or tissue of a subject with cancerous conditions. The cDNA and protein sequences of 93 genes were disclosed. The present invention also relates to assays for diagnosis, prognosis, staging, monitoring, therapeutic treatment, and marker sequence related agents including probes, primers, antibodies, and therapeutic compns.

IT 851927-04-3
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; gene expression profile in colon cancer cells and use of genes as biomarkers for diagnosis, therapy and drug screening)

RN 851927-04-3 CAPLUS

CN Protein (human clone TGFBI colon cancer-specific) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLALL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVIQTNRK YFTNCQKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA
 101 LPLSNLYETL GUVGSGTTQL YTDRTKLRP EMEGPGSFTI FAPSNEAWAS
 151 LPAEVLDSLVS SNNVNIELLNA LRHYHMGRRV LTDELKHGMT LTSMYQNSNI
 201 QIHHPNGIV TVNCARLLKA DHHAATNGVVH LIDKVISIT I NNIQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFKIPS ETLNRLGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLLEVGS GDMLTINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFQAGL
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
 451 HQGTLETGG KKLRFVYRN SLCIENS CIA AHDKRGYGT LFTMDRVLT
 501 PMGTVMVLK GDNRFMSLVA AIQSAGLTET LNRGVYITV FAPTNEAFRAL
 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS
 601 LKNNVVSVNK EPVAEPDIMA TNGVVHVIIT VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L34 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2005:5166 CAPLUS <<LOGINID::20081002>>

DOCUMENT NUMBER: 142:91453

TITLE: Genes showing altered patterns of expression in colon cancer and their use in diagnosis and therapy

INVENTOR(S): Martinez, Robert Vincent; Brown, Eugene; Liu, Wei

PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA

SOURCE: PCT Int. Appl., 167 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004061423	A2	20040722	WO 2004-XA35	20040106
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004061423	A2	20040722	WO 2004-US35	20040106
WO 2004061423	A3	20041216		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ			
PRIORITY APPLN. INFO.:			US 2003-438000P	P 20030106
			WO 2004-US35	A 20040106
AB	Sixty-three genes that show different patterns or levels of expression in normal colon and colon cancer are identified for use in diagnosis and therapy. The genes or gene products may be targets for drug therapy (no data) or as antigens in vaccines. Colon cancer genes of the present invention and their encoded products can be used as markers or prophylactic or therapeutic agents for the detection or treatment of colon cancer. Small interfering RNAs (siRNAs) designed to inhibit expression of the genes are also provided. [This abstract record is the first of eleven records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].			
L34	ANSWER 3 OF 20	CAPLUS	COPYRIGHT 2008 ACS on STN	
ACCESSION NUMBER:	2004:609831	CAPLUS	<<LOGINID:20081002>>	
DOCUMENT NUMBER:	141:155365			
TITLE:	Novel human genes and gene expression products and their use in diagnosis and treatment of colon cancer			
INVENTOR(S):	Astle, Jon H.; Boardman, Lisa Allyn; Burgart, Lawrence J.; Burgess, Christopher C.; Catino, Theodore J.; Dwivedi, Poornima; Lewis, Marcia E.; Molino, Gary A.; Myerow, Susan H.; Thiagalingam, Arunthathi; Thibodeau, Stephen N.			
PATENT ASSIGNEE(S):	Bayer Healthcare LLC, USA; Mayo Foundation for Medical Education & Research			
SOURCE:	U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of U.S. Ser. No. 871,161.			
	CODEN: USXXCO			
DOCUMENT TYPE:	Patent			
LANGUAGE:	English			
FAMILY ACC. NUM. COUNT:	5			
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040146879	A1	20040729	US 2003-610049	20030630 <--
US 6262333	B1	20010717	US 1999-328111	19990608 <--
US 6262334	B1	20010717	US 1999-385982	19990830 <--
US 20030097666	A1	20030522	US 2001-871161	20010531 <--
US 20020144298	A1	20021003	US 2001-879536	20010611 <--

EP 1494031 A2 20050105 EP 2004-253880 20040629
 EP 1494031 A3 20071121
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 JP 2005046137 A 20050224 JP 2004-191089 20040629
 PRIORITY APPLN. INFO.: US 1998-98639P P 19980831 <--
 US 1999-117393P P 19990127 <--
 US 1999-328111 A2 19990608 <--
 US 1999-385982 A1 19990830 <--
 US 2001-871161 A2 20010531 <--
 US 1998-88801P P 19980610 <--
 US 2003-610049 A 20030630
 AB This invention relates to novel human genes, to proteins expressed by the
 genes, and to variants of the proteins. The invention also relates to
 diagnostic assays and therapeutic agents related to the genes and
 proteins, including probes, antisense constructs, and antibodies. The
 subject nucleic acids have been found to be differentially regulated in
 tumor cells, particularly in colon cancer tissue.
 IT 727761-71-9
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (amino acid sequence; human genes and gene expression products and
 their use in diagnosis and treatment of colon cancer)
 RN 727761-71-9 CAPLUS
 CN Protein (human colon cancer-specific gene) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVGITNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPEKKGCPAA
 101 LPLSNLYETL GVGSTTTQL YDTRTEKLRP EMEGPGSFTI FAPSNEAWAS
 151 LPAEVLDSL SNVNIELLNA LRYHMVGRV LTDELKHGMT LTSMYQNSNI
 201 QIHHPYNGIV TVNCARLLKA DHHTATNGVVH LIDKVISITIT NNIQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAEKIPS ETLNRLIGDP
 301 EALRDLNHNH ILKSAMCAEA IVAGLSVETL EGTILEVGCS GDMILINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFQRAGL
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
 451 HGQTLETLLG KKLRFVYVRN SLCIENS CIA AHDKRGRYGT LFTMDRVLTP
 501 PMGTVMVDVL GDNRFMSMLVA AIQSAGLTET LNRREGVYTVF APTNEAFRAL
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLE SLQGEKLEVS
 601 LKNVVSVNK EPVAEPDIMA TNGVHVHITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L34 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:569041 CAPLUS <LOGINID:20081002>>
 DOCUMENT NUMBER: 141:118261
 TITLE: Method for detecting presence of colorectal cancer
 using TIMP1
 INVENTOR(S): Burgess, Christopher C.; Johnson, Karen Ann;
 Brown-Semelle, Cherill Lynn Andrea; Astle, John H.;
 Boardman, Lisa Elaine; Baggard, Lawrence J.; Catino,
 Theodore J.; Dwivedi, Poornima; Huntress, Mary Ann;
 Meimonis, Peter J.; Molino, Gary A.; Myerow, Susan H.;
 Thiadlingam, Arunthathi; Cibodo, Steven N.; Lewis,
 Marcia E.
 PATENT ASSIGNEE(S): Bayer Healthcare, LLC, USA; Mayo Foundation for
 Medical Education and Research
 SOURCE: Jpn. Kokai Tokkyo Koho, 90 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004198419	A	20040715	JP 2003-414126	20031212 <--
US 20040157278	A1	20040812	US 2003-734564	20031212 <--
EP 1439393	A2	20040721	EP 2003-257868	20031215 <--
EP 1439393	A3	20040811		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20080194043	A1	20080814	US 2008-52760	20080321 <--
PRIORITY APPLN. INFO.:				
			US 2002-433554P	P 20021213 <--
			US 2003-491397P	P 20030731
			US 2003-700439	A1 20031104
			US 2003-734564	A1 20031212
AB	The present invention relates to a method for detecting the presence of colorectal cancer in an individual, wherein colorectal cancer is detected by detecting the presence of Regla or TIMP1 nucleic acid or amino acid mol. in a clin. sample obtained from the patient, wherein Regla or TIMP1 expression is indicative of the presence of colorectal cancer. The invention further relates to a method for detecting the presence of colorectal cancer in an individual, wherein colorectal cancer is detected by detecting the presence of Regla or TIMP1 nucleic acid or amino acid mol. in a clin. sample, in addition to detecting the presence of one or more addnl. colorectal cancer-associated markers.			
IT	722554-69-0, protein (human TGFBI gene-coding) RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (amino acid sequence; method for diagnosing colorectal cancer using TIMP1 or Regla)			
RN	722554-69-0 CAPLUS			
CN	protein (human TGFBI gene-coding) (9CI) (CA INDEX NAME)			

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCPAA
 101 LPLSNLYETL GVGSGTTTQL YTDRTKLRP EMEGPGSFTI FAPSNAAWAS
 151 LPAEVLDSL SVNNIELLNA LRYHVMGRRV LTDELKHGMT LTSMYQNSNI
 201 QIHHYPNGIV TVNCARLLKA DHATNGVVH LDKVISTIT NNIQIIEIE
 251 DTFETLRAAV AASGLNTHLE GNGQYTLAP TNEAFEKIPS ETILNRILGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLVGVCS GMDLTINGKA
 351 IISNKDILAT NGVIHYDEL LIPDSAKTL ELAAESDVST AIDLFRQAGL
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KQPLASKYLY
 451 HGQTLETGG KKLRFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLT
 501 PMGTVMVDLV GDNRFMSMLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SIQGGKLEVS
 601 LKNNVVSVNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L34 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2004:534405 CAPLUS <<LOGINID:20081002>>
 DOCUMENT NUMBER: 141:69775
 TITLE: Specific protein markers useful for diagnosis of pancreatic cancer and screening methods

INVENTOR(S): Chen, Jie; Hu, Liping; Liu, Tong Hua; Lu, Zhao Hui; Shen, Yan
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.; Sinogenomax Co. Ltd.
 Chinese National Human Genomecenter
 SOURCE: PCT Int. Appl., 381 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055519	A2	20040701	WO 2003-EP14057	20031211 <--
WO 2004055519	A3	20041104		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003294828	A1	20040709	AU 2003-294828	20031211 <--
US 20040219572	A1	20041104	US 2003-733969	20031211 <--
CN 1726395	A	20060125	CN 2003-80106539	20031211 <--

PRIORITY APPLN. INFO.: EP 2002-28058 A 20021217 <--
 EP 2003-25237 A 20031105
 WO 2003-EP14057 W 20031211

AB The present invention provides polypeptides which are up- or down-regulated in pancreatic cancer and which can be used as markers for diagnosis of pancreatic cancer. Thus, 110 protein markers are identified in pancreatic adenocarcinoma patients by 2-dimensional electrophoresis and MALDI-TOF mass spectrometry. The invention also provides an in vitro method for the diagnosis of pancreatic cancer and/or the susceptibility to pancreatic cancer comprising the steps of (a) obtaining a biol. sample; and (b) detecting and/or measuring the increase of one or more polypeptides as disclosed herein. Furthermore, screening methods relating to inhibitors and antagonists of the specific polypeptides disclosed herein are provided.

IT 712410-93-0
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; specific protein markers useful for diagnosis of pancreatic cancer and screening methods)

RN 712410-93-0 CAPLUS

CN Cell adhesion molecule β ig-h3 (TGF- β -induced gene h3 (human precursor) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLALL ALALALGPAA TLGAPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVGISTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGPAA
 101 LPLSNLYETL GVVGSITTQL YDRTTEKLRP EMEGPGSFIT FAPSNEAWAS
 151 LPAEVLDSLIV SNVNIELLNA LRYHMVGRVR LTDELKHGMT LTSMYQNSNI
 201 QIHHPNGVIV TVNCARLLKA DHHATNGVVH LIDKVISIT NNIQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYITLLAP TNEAFEEKIPS ETILNRLGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLVGCSD GDMLTINKGA
 351 IISNKDILAT NGVIHYIDEL LIPDSATKLF ELAAESDVST AIDLFERQAGL
 401 GNLHSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY

451 HGQTLLETGG KKLRFVYRN SLCIENS CIA AHDKRGRYGT LFTMDRVLTP
 501 PMGTVM DVLK GDNRF SMLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGGKLEVS
 601 LKNNVSVNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L34 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2004:354746 CAPLUS <LOGINID:20081002>
 DOCUMENT NUMBER: 140:373912
 TITLE: Immunostimulatory cytokine or encoding nucleic acid in
 combination with antigen presenting cells for treating
 cancer, metastasis and infection
 INVENTOR(S): Lotze, Michael T.; Tahara, Hideaki
 PATENT ASSIGNEE(S): University of Pittsburgh of the Commonwealth System of
 Higher Education, USA
 SOURCE: PCT Int. Appl., 169 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004034995	A2	20040429	WO 2003-US32827	20031015 <--
WO 2004034995	A9	20040610		
WO 2004034995	A3	20050120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003290528	A1	20040504	AU 2003-290528	20031015 <--
US 20040247578	A1	20041209	US 2003-688845	20031015 <--
PRIORITY APPLN. INFO.:			US 2002-418865P	P 20021015 <--
			WO 2003-US32827	W 20031015
AB	Methods and reagents for treating tumors, metastases, and infectious lesions by coadministration of antigen presenting cells and immunostimulatory cytokines or nucleic acid encoding an immunostimulatory cytokine into or near the site of the tumor or infectious lesion are described.			
IT	683836-05-7 RL: PRP (Properties) (unclaimed protein sequence; immunostimulatory cytokine or encoding nucleic acid in combination with antigen presenting cells for treating cancer, metastasis and infection)			
RN	683836-05-7 CAPLUS			
CN	11: PN: WO2004034995 SEQID: 77 unclaimed protein (9CI) (CA INDEX NAME)			

SEQ 1 MALFVRL LAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVIQTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCFAA
 101 LPLSNLYETL GVVGSTTTQL YTDRTKELRP EMEGPGSFTI FAPSNEAWAS

151 LPAEVLDSL V SNVNIELLNA LRYHVMGRRV LTDELKHGMT LTSMYQNSNI
 201 QIHHYPNGIV TVNCARLLKA DHHATNGVVH LIDKVISIT NNIQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFKIPS ETLNRLGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTLEVGCS GDMLTINGKA
 351 IISNKDILAT NGVIHYDEL LIPDSAKTLF ELAASDVST AIDLFRQAGL
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKVLY
 451 HGQTLRLTGG KKLRFVYVRN SLCIENSCIA AHDKRGYGT LFTMDRVLT
 501 PMGTVMNVLV GDMRFSMLVA AIQSAGLET LNREGVYTVF APTNEAFRAL
 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS
 601 LKNNVVSVMK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQSRVRL APVYQKLLER MKH

L34 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2004:308357 CAPLUS <<LOGINID::20081002>>

DOCUMENT NUMBER: 140:333596

TITLE: Differentially expressed nucleic acids and their encoded proteins and their uses for the diagnosis and treatment of tumor

INVENTOR(S): Wu, Thomas D.; Zhang, Zemin; Zhou, Yan

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 7273 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030615	A2	20040415	WO 2003-US28547	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500687	A1	20040415	CA 2003-2500687	20030929
WO 2004030615	A2	20040415	WO 2003-XA28547	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003295328	A1	20040423	AU 2003-295328	20030929
EP 1594447	A2	20051116	EP 2003-786510	20030929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516089	T	20060622	JP 2004-541530	20030929
US 20070224201	A1	20070927	US 2005-529351	20050325

PRIORITY APPLN. INFO.:

US 2002-414971P P 20021002
WO 2003-US28547 W 20030929

AB The present invention provides a large number of specific cDNA sequences which are upregulated in certain tumor tissues as compared to their normal tissue counterparts and therefore useful for the diagnosis and treatment of tumor in mammals. An expressed sequence tag (EST) DNA database was searched and interesting EST sequences identified by GEFIS (gene expression profiling in silico), a bioinformatics tool that characterizes genes of interest for new cancer therapeutic targets. Using this type of screening bioinformatics, various tumor-associated antigenic target (TAT) proteins (and their encoding nucleic acid mols). were identified as being significantly overexpressed in particular type of cancer or certain cancers as compared to other cancers and/or normal non-cancerous tissues. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L34 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:290482 CAPLUS <LOGINID:20081002>>

DOCUMENT NUMBER: 140:316226

TITLE: Nucleic acid and encoded protein sequences that are differentially expressed in psoriatic skin and their use for diagnosis and treatment of psoriasis

INVENTOR(S): Bodary, Sarah; Clark, Hilary; Jackman, Janet; Schoenfeld, Jill; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 3068 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028479	A2	20040408	WO 2003-US30907	20030925
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2499843	A1	20040408	CA 2003-2499843	20030925
AU 2003279084	A1	20040419	AU 2003-279084	20030925
EP 1585482	A2	20051019	EP 2003-770594	20030925
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006513700	T	20060427	JP 2004-540290	20030925
US 20070042945	A1	20070222	US 2005-529348	20050325
PRIORITY APPLN. INFO.:			US 2002-414006P P 20020925	
			WO 2003-US30907 W 20030925	

AB The present invention provides a large number of cDNA and protein sequences that are differentially expressed in psoriatic tissue. Affymetrix microarrays are used to identify genes whose expression are up-regulated or down-regulated in psoriatic skin vs. non-lesional skin, thus comparing expression profiles of non-lesional skin and psoriatic skin from the same

patient, and also comparing against normal skin biopsies of normal healthy donors as a further control. The nucleic acid and protein compns. are useful in the diagnosis and/or treatment of psoriasis, and in screening for candidate inhibitors of psoriasis.

L34 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2003:913280 CAPLUS <<LOGINID::20081002>>
 DOCUMENT NUMBER: 139:379453
 TITLE: Genes showing altered patterns of expression in multiple sclerosis and their diagnostic and therapeutic uses
 INVENTOR(S): Dangond, Fernando; Hwang, Daehee
 PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc., USA
 SOURCE: PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095618	A2	20031120	WO 2003-US14462	20030507
WO 2003095618	A3	20041021		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040018522	A1	20040129	US 2003-430762	20030506
AU 2003228936	A1	20031111	AU 2003-228936	20030507
PRIORITY APPLN. INFO.:			US 2002-379284P	P 20020509
			US 2003-430762	A1 20030506
			WO 2003-US14462	W 20030507

AB The present invention identifies a number of gene markers whose expression is altered in multiple sclerosis (MS). These markers can be used to diagnose or predict MS in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent MS development or progression. Genes were identified by determination of expression profiling. A large number of genes showing altered patterns of expression were identified, with the most discriminatory genes being those for: phosphatidylinositol transfer protein, inducible nitric oxide synthase, CIC-1 (CLCN1) muscle chloride channel protein, placental bikunin (AMBP), receptor kinase ligand LERK-3/Ephrin-A3, GATA-4, thymopoietin, transcription factor E2f-2, S-adenosylmethionine synthetase, carcinoembryonic antigen, the ret oncogene, a G protein-linked receptor (clone GPCR W), GTP- binding protein RALB, tyrosine kinase Syk, LERK-2/Ephrin-B1, ELK1 tyrosine kinase oncogene, transcription factor SL1, phospholipase C, gastricsin (progastricsin), and the D13S824E locus.

L34 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2003:747872 CAPLUS <<LOGINID::20081002>>
 DOCUMENT NUMBER: 139:256367
 TITLE: Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather;

Meagher, Madeleine Joy; Stolk, John; Benson, Darin R.;
 Wang, Tongtong
 PATENT ASSIGNEE(S): Corixa Corporation, USA
 SOURCE: U.S., 140 pp., Cont.-in-part of U.S. Ser. No. 347,496.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6623923	B1	20030923	US 1999-401064	19990922 <--
US 6284241	B1	20010904	US 1998-221298	19981223 <--
CA 2356987	A1	20000629	CA 1999-2356987	19991223 <--
WO 2000037643	A2	20000629	WO 1999-US30909	19991223 <--
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144632	A2	20011017	EP 1999-967625	19991223 <--
EP 1144632	A3	20011107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533082	T	20021008	JP 2000-589697	19991223 <--
EP 1715043	A2	20061025	EP 2006-2432	19991223 <--
EP 1715043	A3	20070110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1767636	A2	20070328	EP 2006-25304	19991223 <--
EP 1767636	A3	20070613		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, AL, LT, LV, MK, RO, SI				
US 20020110547	A1	20020815	US 2001-833263	20010410 <--
US 20020076414	A1	20020620	US 2001-922217	20010803 <--
US 20020182191	A1	20021205	US 2001-25380	20011219 <--
US 20050260177	A1	20051124	US 2005-108172	20050415 <--
PRIORITY APPLN. INFO.:			US 1998-221298	A2 19981223 <--
			US 1999-347496	A2 19990702 <--
			US 1999-401064	A 19990922 <--
			US 1999-444242	A 19991119 <--
			US 1999-444252	A2 19991119 <--
			US 1999-454150	A 19991202 <--
			EP 1999-967625	A3 19991223 <--
			WO 1999-US30909	W 19991223 <--
			US 1999-476296	A2 19991230 <--
			US 2000-480321	A2 20000110 <--
			US 2000-504629	A2 20000215 <--
			US 2000-519444	A2 20000306 <--
			US 2000-444252	A2 20000410 <--
			US 2000-575251	A2 20000519 <--
			US 2000-609448	A2 20000629 <--
			US 2000-649811	A2 20000828 <--
			US 2001-833263	A2 20010410 <--
			US 2001-922217	A2 20010803 <--
			US 2001-25380	B1 20011219 <--

AB Comps. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Comps. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such comps. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 603206-84-4P
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence; tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer)

RN 603206-84-4 CAPLUS

CN Colon tumor-associated protein (human clone US6623923-SEQID-121) (9CI)
 (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLOHSRLR GRQHGPNVCA
 51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPEKGCPAA
 101 LPLSNLYETL GVGVSTTTQL YTDRTKLRP EMEGPGSFTI FAPSNEAWAS
 151 LPAEVLDSL SVNIELLNA LRYHMGRRV LTDELKHGMI LISMVQNSNI
 201 QIHHPNGIV TVNCARLLKA DHHAATNGVVH LIDKVISITIT NNIQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETNLNRLGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLVGCSS GDMLTINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFQAGL
 401 GNHLGSGERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
 451 HGQTLETGG KKLRFVYVRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTP
 501 PMGTVMDLVK GDNRFSLVA AIQSAGLTET LNREGVYTVF APTNEAFRLP
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS
 601 LKNNVSVNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:626612 CAPLUS <<LOGINID:20081002>>
 Correction of: 2003:472599

DOCUMENT NUMBER: 139:129181
 Correction of: 139:48232

TITLE: Differentially expressed genes for identification, assessment, prevention, and therapy of colon cancer

INVENTOR(S): Berger, Allison; Guillemette, Tracy L.; Schlegel, Robert; Monahan, John E.; Kamatkar, Shubhangi; Thibodeau, Stephen; Burgart, Lawrence J.

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050243	A2	20030619	WO 2002-US37431	20021121 <--
WO 2003050243	A3	20040401		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002357747	A1	20030623	AU 2002-357747	20021121 <--
US 20030148410	A1	20030807	US 2002-301822	20021121 <--
US 20050266493	A1	20051201	US 2005-186284	20050721 <--
PRIORITY APPLN. INFO.:			US 2001-339971P	P 20011210 <--
			US 2002-361978P	P 20020305 <--
			US 2002-381988P	P 20020520 <--
			US 2002-301822	B1 20021121 <--
			WO 2002-US37431	W 20021121 <--
AB	The invention relates to newly discovered nucleic acids and proteins that are up-regulated in colon cancer. The 114 markers were identified by transcriptional profiling with RNA derived from 21 normal colon samples, 4 adenomatous polyps, and 25 colon cancer samples using nylon arrays of 44,200 clones, including 30,000 IMAGE clones, 14,000 clones from cDNA libraries generated at Millennium Pharmaceuticals, Inc., and 200 control genes. Higher than normal levels of expression of any of these markers or combination of these markers correlates with the presence of colon cancer. Thus, compns., kits, and methods for detecting, characterizing, preventing, and treating human colon cancers are provided. The present invention claims a total of 228 sequences, but the Sequence Listing was not made available on publication of the patent application.			
IT	568626-58-4 RL: PRP (Properties) (unclaimed protein sequence; differentially expressed genes for identification, assessment, prevention, and therapy of colon cancer)			
RN	568626-58-4 CAPLUS			
CN	99: PN: WO03050243 SEQID: 201 unclaimed protein (9CI) (CA INDEX NAME)			
SEQ	1 MALFVRLIAL ALALALGPAA TLGAPKSPY QLVLQHSRLR GRQHGPNVCA 51 VQKVGITNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGPFAA 101 LPLSNLYETL GVGSGTITQL YDTRTEKLRP EMEGPGSFTI FAPSNEAWAS 151 LPAEVLDSLIV SNVNIELLNA LRYHMVGRVR LTDELKHGMT LTSMYQNSNI 201 QIHHPNGNIV TVNCARLLKA DHHAATNGVVH LIDKVISITIT NNIQIIEIE 251 DTFETLRAAV AASGLNTMLE GNGQYITLLAP TNEAFEEKIPS ETLNRLIGDP 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLVGCSS GMMLTINGKA 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAASDVST AIDLFQAGL 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KPQLASKVLY 451 HGQTLETLLG KKLRFVYVRN SLCIENSCLIA AHDKRGRYGT LFTMDRVLT 501 PMGTVMVLK GDNRFMSLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS 601 LKNNVSVNKN EPVAPEDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA 651 LEIFKQASAF SRASQSRVRL APVYQKLIER MKH			

L34 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:442069 CAPLUS <<LOGINID:20081002>>
 DOCUMENT NUMBER: 139:18315
 TITLE: Gene expression profiles useful for methods of
 diagnosis of cancer and screening for modulators of
 cancer
 INVENTOR(S): Afar, Daniel; Aziz, Natasha; Ginsburg, Wendy M.; Gish,
 Kurt C.; Glynne, Richard; Hevezi, Peter A.; Mack,
 David H.; Murray, Richard; Watson, Susan R.; Wilson,
 Keith E.; Zlotnik, Albert
 PATENT ASSIGNEE(S): Eos Biotechnology, Inc., USA
 SOURCE: PCT Int. Appl., 1385 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 38
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042661	A2	20030522	WO 2002-XK36810	20021113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1721977	A2	20061115	EP 2006-7721	20020917
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR				
US 20070042360	A1	20070222	US 2002-245882	20020917
WO 2003042661	A2	20030522	WO 2002-US36810	20021113
WO 2003042661	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040197325	A1	20041007	US 2003-741657	20031219
US 7276372	B2	20071002		
US 20070059748	A1	20070315	US 2006-516476	20060906
US 20070154928	A1	20070705	US 2007-625458	20070122
PRIORITY APPLN. INFO.:			US 2001-350666P	P 20011113
			US 2001-335394P	P 20011115
			US 2001-332464P	P 20011121
			US 2001-334393P	P 20011129
			US 2001-340376P	P 20011214
			US 2002-347211P	P 20020108
			US 2002-347349P	P 20020110
			US 2002-356714P	P 20020213
			US 2002-359077P	P 20020220
			US 2002-368809P	P 20020329

US 2002-370110P P 20020404
 US 2002-372246P P 20020412
 US 2002-386614P P 20020605
 US 2002-396839P P 20020716
 US 2002-397775P P 20020722
 US 2002-397845P P 20020722
 US 2002-409450P P 20020909
 WO 2002-US36810 W 20021113
 US 2001-299234P P 20010618
 US 2001-315287P P 20010827
 US 2001-323469P P 20010917
 US 2001-323887P P 20010920
 US 2001-325114P P 20010925
 US 2001-340944P P 20011029
 US 2002-355145P P 20020208
 US 2002-355257P P 20020208
 US 2002-369899P P 20020404
 US 2002-173999 A 20020617
 EP 2002-766297 A3 20020917
 US 2002-245882 A1 20020917
 US 2002-435618P P 20021220

AB Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases, or are otherwise regulated in disease. Mol. profiles of various normal and cancerous tissues were determined and analyzed using the Affymetrix/Eos Hu3 GeneChip array comprising .apprx.58,680 probesets. Related methods and compns. that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions. [This abstract record is one of twelve records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L34 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:242516 CAPLUS <<LOGINID:20081002>>
 DOCUMENT NUMBER: 138:266955
 TITLE: Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma
 INVENTOR(S): James, Robert; Henry, Julianne; Kazenwadel, Jan; Van Host, Pellekaan Nick; MacPherson, Anne; O'Connor, Susan
 PATENT ASSIGNEE(S): Medimolecular Pty. Ltd., Australia
 SOURCE: PCT Int. Appl., 430 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025214	A1	20030327	WO 2002-AU1258	20020913 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,			

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002325088	A1	20030401	AU 2002-325088	20020913 <--
AU 2002325088	B2	20070809		
EP 1438427	A1	20040721	EP 2002-757979	20020913 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

US 20050053967	A1	20050310	US 2004-800322	20040312 <--
AU 2007201611	A1	20070503	AU 2007-201611	20070412 <--

PRIORITY APPLN. INFO.: US 2001-322288P P 20010914 <--
AU 2002-325088 A3 20020913 <--
WO 2002-AU1258 W 20020913 <--

AB The present invention relates generally to novel nucleic acid mols., the levels and/or patterns of expression of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm and to derivs., homologs or analogs of said mols. More particularly, the present invention is directed to novel nucleic acid mols., the levels of expression of which are indicative of the onset and/or progression of a gastrointestinal tract neoplasm, such as an adenoma, and to derivs., homologs or analogs of said mols. The present invention is further directed to isolated proteins encoded thereby and to derivs., homologs, analogs, chemical equivalent and mimetics thereof. The identification of

adenoma markers and adenoma markers together with identification of their expression uplift levels and expression profile can now be correlated to disease stage and/or cancer invasiveness. The mols. of the present invention are useful in a range of prophylactic, therapeutic, and/or diagnostic applications including, but not limited to, those relating to the diagnosis and/or treatment of colorectal neoplasms such as colorectal adenomas. In a related aspect, the present invention is directed to a method of screening a subject for the onset, predisposition to the onset, and/or progression of a neoplasm by screening for modulation in the level of expression of one or more nucleic acid mol. markers.

IT 503193-38-2
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma)

RN 503193-38-2 CAPLUS

CN Adenoma-associated protein (human clone 4-11e) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLOHSRLR GRQHGPNVCA
51 VQKVIQTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPEKGCPAA
101 LPLSNLYETL GVVGSTTTQL YTDRTKLRP EMEGPGSFTI FAPSNEAWAS
151 LPAEVLDSL SVNVIELLNA LRYHVMGRRV LTDELKHGMT LTSMYQNSNI
201 QIHHPNGVIV TVNCARLLKA DHHAATNGVVH LIDKVISITIT NNIQIIEIE
251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETILNRLIGDP
301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLVVGCS GDMLTINKGA
351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFQAGL
401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLRNHII KPQLASKYLY
451 HGQTLETLGG KKLRFVYVRN SLCIENS CIA AHDKRGRYGT LFTMDRVLTP
501 PMGTVMVDLVK GDNRFSLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGDKLEVS
601 LKNVVSVNKK EPVAEPDIMA TNGVHVHITN VLQPPANRPQ ERGDELADSA
651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:242452 CAPLUS <<LOGINID:20081002>>
 DOCUMENT NUMBER: 138:282427
 TITLE: Gene expression profiles useful in methods of
 diagnosis of cancer compositions and methods of
 screening for modulators of cancer
 INVENTOR(S): Afar, Daniel; Aziz, Natasha; Gish, Kurt C.; Hevezi,
 Peter A.; Mack, David H.; Wilson, Keith E.; Zlotnik,
 Albert
 PATENT ASSIGNEE(S): EOS Biotechnology, Inc., USA
 SOURCE: PCT Int. Appl., 767 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 38
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025138	A2	20030327	WO 2002-US29560	20020917 <--
WO 2003025138	A3	20030508		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2459219	A1	20030327	CA 2002-2459219	20020917 <--
WO 2003025138	A2	20030327	WO 2002-XA29560	20020917 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003025138	A2	20030327	WO 2002-XB29560	20020917 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003025138	A2	20030327	WO 2002-XC29560	20020917 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003025138	A2	20030327	WO 2002-XD29560	20020917 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003025138	A2	20030327	WO 2002-XE29560	20020917 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003025138	A2	20030327	WO 2002-XF29560	20020917 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003025138	A2	20030327	WO 2002-XG29560	20020917 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003025138	A2	20030327	WO 2002-XH29560	20020917 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002330039	A1	20030401	AU 2002-330039	20020917 <--
EP 1434881	A2	20040707	EP 2002-766297	20020917 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2005518782 T 20050630 JP 2003-529912 20020917 <--
 EP 1721977 A2 20061115 EP 2006-7721 20020917 <--
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
 LI, LU, MC, NL, PT, SE, SK, TR
 US 20070042360 A1 20070222 US 2002-245882 20020917 <--
 US 20040197325 A1 20041007 US 2003-741657 20031219 <--
 US 7276372 B2 20071002
 US 20070059748 A1 20070315 US 2006-516476 20060906 <--
 US 20070154928 A1 20070705 US 2007-625458 20070122 <--
 PRIORITY APPLN. INFO.: US 2001-323469P P 20010917 <--
 US 2001-323887P P 20010920 <--
 US 2001-350666P P 20011113 <--
 US 2002-355145P P 20020208 <--
 US 2002-355257P P 20020208 <--
 US 2002-372246P P 20020412 <--
 US 2001-299234P P 20010618 <--
 US 2001-315287P P 20010827 <--
 US 2001-325114P P 20010925 <--
 US 2001-340944P P 20011029 <--
 US 2002-369899P P 20020404 <--
 US 2002-173999 A 20020617 <--
 EP 2002-766297 A3 20020917 <--
 US 2002-245882 A1 20020917 <--
 WO 2002-US29560 W 20020917 <--
 US 2002-435618P P 20021220 <--

AB Described herein are genes whose expression are up-regulated or
 down-regulated in specific cancers, including acute lymphocytic leukemia,
 glioblastoma, glioblastoma multiforme, glioma, kidney cancer, stomach
 cancer, melanoma, and benign nevi. Mol. profiles of various normal and
 cancerous tissues were determined and analyzed using the Affymetrix/Eos Hu01
 and Hu03 GeneChip microarrays containing 35,403 and 59,680 probe sets, resp.
 Related methods and compns. that can be used for diagnosis and treatment
 of those cancers are disclosed. Also described herein are methods that
 can be used to identify modulators of selected cancers. [This abstract
 record is one of nine records for this document necessitated by the large
 number of index entries required to fully index the document and publication
 system constraints.]

IT 503636-40-6
 RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU
 (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES
 (Uses)
 (amino acid sequence; gene expression profiles useful in methods of
 diagnosis of cancer compns. and methods of screening for
 modulators of cancer)

RN 503636-40-6 CAPIUS
 CN Tumor-associated protein (human clone W003025138-SEQID-279) (9CI) (CA
 INDEX NAME)

SEQ 1 MALFVRLALL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVIGITNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEGKCPAA
 101 LPLSNLYETL GVGSGITTQL YDRTKEKLR EMEGPGSFETI FAPSNEAWAS
 151 LPAEVLDSL SVNVIELLNA LRYHMGVRRV LTDELKHGMT LTSMYQNSNI
 201 QIHHYPNGIV TVNRCARLLKA DHHTATNGVVH LIDKVISITIT NNIQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRIIGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLLEVGS GDMLTINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFRQAGL
 401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KQOLASKVLY
 451 HGQTLETLGG KKLRFVYVRN SLCIENS CIA AHDKRGRYGT LFTMDRVLTP

501 PMGTVMVLK GDNRFSLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGGKLEVS
 601 LKNNVSVNKK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQSRVRL APVYQKLLER MKH

L34 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:928019 CAPLUS <<LOGINID:20081002>>
 DOCUMENT NUMBER: 138:1132
 TITLE: Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John A.; Wang, Tongtong; Jiang, Yuqiu; Smith, Carole L.; King, Gordon E.; Wang, Aijun; Clapper, Jonathan D.; Skeiky, Yasir A. W.; Fanger, Gary R. C.; Vedvick, Thomas S.; Carter, Darrick
 PATENT ASSIGNEE(S): Corixa Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.--in-part of U.S. Ser. No. 922,217.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020182191	A1	20021205	US 2001-25380	20011219
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020076414	A1	20020620	US 2001-922217	20010803
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002256186	A1	20021028	AU 2002-256186	20020409
US 20050260177	A1	20051124	US 2005-108172	20050415
PRIORITY APPLN. INFO.:				
			US 1998-221298	A2 19981223
			US 1999-347496	A2 19990702
			US 1999-401064	A2 19990922

US 1999-444252	A2 19991119
US 1999-454150	B2 19991202
WO 1999-US30909	W 19991223
US 1999-476296	B2 19991230
US 2000-480321	B2 20000110
US 2000-504629	B2 20000215
US 2000-519444	B2 20000306
US 2000-575251	B2 20000519
US 2000-609448	A2 20000629
US 2000-649811	A2 20000828
US 2001-833263	A2 20010410
US 2001-922217	A2 20010803
US 1999-444242	A 19991119
US 2000-444252	A2 20000410
US 2001-25380	A 20011219
WO 2002-US11475	W 20020409

AB Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L34 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:813878 CAPLUS <<LOGINID:20081002>>

DOCUMENT NUMBER: 137:324213

TITLE: Colon tumor proteins, antibodies and oligonucleotides for immunotherapy and diagnosis of colon cancer

INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John A.; Wang, Tongtong; Jiang, Yuqiu; Smith, Carole L.; King, Gordon E.; Wang, Aijun; Clapper, Jonathan D.; Skeiky, Yasir Aw; Fanger, Gary R.; Vedvick, Thomas S.; Carter, Darrick

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 537 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 20020110547 A1 20020815 US 2001-833263 20010410
 US 20020076414 A1 20020620 US 2001-922217 20010803
 US 20020182191 A1 20021205 US 2001-25380 20011219
 AU 2002256186 A1 20021028 AU 2002-256186 20020409
 PRIORITY APPLN. INFO.: US 2001-833263 A 20010410
 US 2001-922217 A 20010803
 US 2001-25380 A 20011219
 US 1998-221298 A2 19981223
 US 1999-347496 A2 19990702
 US 1999-401064 A2 19990922
 US 1999-444252 A2 19991119
 US 1999-454150 A2 19991202
 WO 1999-US30909 A2 19991223
 US 1999-476296 A2 19991230
 US 2000-480321 A2 20000110
 US 2000-504629 A2 20000215
 US 2000-519444 A2 20000306
 US 2000-444252 A2 20000410
 US 2000-575251 A2 20000519
 US 2000-609448 A2 20000629
 US 2000-649811 A2 20000828
 WO 2002-US11475 W 20020409
 AB Comps. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Comps. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such comps. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L34 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:616199 CAPLUS <<LOGINID:20081002>>
 DOCUMENT NUMBER: 137:151147
 TITLE: Tumor-associated nucleic acids and proteins for immunotherapy and diagnosis of colon cancer
 INVENTOR(S): Wang, Aijun; Clapper, Jonathan D.; Stolk, John A.; Meagher, Madeleine Joy
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 649,811.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020110547	A1	20020815	US 2001-833263	20010410
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,

	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,	
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
US 20020076414	A1 20020620	US 2001-922217 20010803
US 20020182191	A1 20021205	US 2001-25380 20011219
WO 2002083070	A2 20021024	WO 2002-US11475 20020409
WO 2002083070	A3 20041111	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,	
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,	
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,	
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,	
	UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,	
	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,	
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2002256186	A1 20021028	AU 2002-256186 20020409
US 20050260177	A1 20051124	US 2005-108172 20050415
PRIORITY APPLN. INFO.:		US 1998-221298 A2 19981223
		US 1999-347496 A2 19990702
		US 1999-401064 A2 19990922
		US 1999-454150 A2 19991202
		WO 1999-US30909 A2 19991223
		US 1999-476296 A2 19991230
		US 2000-480321 A2 20000110
		US 2000-504629 A2 20000215
		US 2000-519444 A2 20000306
		US 2000-444252 A2 20000410
		US 2000-575251 A2 20000519
		US 2000-609448 A2 20000629
		US 2000-649811 A2 20000828
		US 1999-444242 A 19991119
		US 1999-444252 A2 19991119
		US 2001-833263 A2 20010410
		US 2001-922217 A2 20010803
		US 2001-25380 A 20011219
		WO 2002-US11475 W 20020409
AB	Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Thus, polypeptides differentially expressed in colon tumors are isolated and characterized by PCR-based subtraction and microarray anal. of cDNA libraries, as well as mouse antisera. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.	
L34	ANSWER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN	
ACCESSION NUMBER:	2002:466537 CAPLUS <<LOGINID::20081002>>	
DOCUMENT NUMBER:	137:42650	
TITLE:	Tumor-associated proteins and their cDNA sequences and uses for immunotherapy and diagnosis of colon cancer	
INVENTOR(S):	Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John A.; Wang, Tongtong; Jiang, Yuqiu; Smith, Carole L.; King, Gordon E.; Wang, Aijun; Clapper, Jonathan D.	
PATENT ASSIGNEE(S):	Corixa Corporation, USA	
SOURCE:	U.S. Pat. Appl. Publ., 50 pp., Cont.-in-part of U.S. Ser. No. 833,263.	

DOCUMENT TYPE: CODEN: USXXCO
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020076414	A1	20020620	US 2001-922217	20010803
US 6284241	B1	20010904	US 1998-221298	19981223
US 6623923	B1	20030923	US 1999-401064	19990922
WO 2000037643	A2	20000629	WO 1999-US30909	19991223
WO 2000037643	A3	20010809		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 20020110547	A1	20020815	US 2001-833263	20010410
US 20020182191	A1	20021205	US 2001-25380	20011219
WO 2002083070	A2	20021024	WO 2002-US11475	20020409
WO 2002083070	A3	20041111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
AU 2002256186	A1	20021028	AU 2002-256186	20020409
US 20050260177	A1	20051124	US 2005-108172	20050415

PRIORITY APPLN. INFO.:

US 1998-221298	A2	19981223
US 1999-347496	A2	19990702
US 1999-401064	A2	19990922
US 1999-454150	B2	19991202
WO 1999-US30909	W	19991223
US 1999-476296	A2	19991230
US 2000-480321	B2	20000110
US 2000-504629	A2	20000215
US 2000-519444	A2	20000306
US 2000-444252	A2	20000410
US 2000-575251	A2	20000519
US 2000-609448	A2	20000629
US 2000-649811	A2	20000828
US 2001-833263	A2	20010410
US 1999-444242	A	19991119
US 1999-444252	A2	19991119
US 2001-922217	A2	20010803
US 2001-25380	A	20011219
WO 2002-US11475	W	20020409

AB Comps. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Thus, colon tumor-associated proteins are isolated by PCR-based subtraction and microarray anal., use of SCID mouse antisera, and conventional subtraction. Comps. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an

antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such comps. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L34 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:507728 CAPLUS <<LOGINID::20081002>>
 DOCUMENT NUMBER: 135:121178
 TITLE: Identification of colon cancer-associated proteins for immunotherapy and diagnosis
 INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John A.; King, Gordon E.; Wang, Tongtong; Jiang, Yuqiu
 PATENT ASSIGNEE(S): Corixa Corporation, USA
 SOURCE: PCT Int. Appl., 472 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049716	A2	20010712	WO 2000-US35596	20001229 <--
WO 2001049716	A3	20020131		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2396036 A1 20010712 CA 2000-2396036 20001229 <-- EP 1242598 A2 20020925 EP 2000-989592 20001229 <-- R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR PRIORITY APPLN. INFO.: US 1999-476296 A 19991230 <-- US 2000-480321 A 20000110 <-- US 2000-504629 A 20000215 <-- US 2000-519444 A 20000306 <-- US 2000-575251 A 20000519 <-- US 2000-609448 A 20000629 <-- US 2000-649811 A 20000828 <-- WO 2000-US35596 W 20001229 <--				
AB The authors disclose the use of a cDNA library and subtractive PCR to identify a number of genes, and their proteins, which are overexpressed in human colon tumors. In addition, soluble tumor proteins expressed in serum of colon tumor-bearing SCID mice were used to generate polyclonal antibodies for probing a cDNA expression library. IT 148710-76-3, Protein (human clone β ig-h3 transforming growth factor β -induced precursor reduced) RL: ANT (Analyte); ARG (Analytical reagent use); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (amino acid sequence; identification and immunogenicity of human colon tumor-associated antigens) RN 148710-76-3 CAPLUS				

CN Protein (human clone β ig-h3 transforming growth factor β -induced precursor reduced) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLOHSRLR GRQHGPNVCA
 51 VQKVGITNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPGEKGCFAA
 101 LPLSNLYETL GVVGSTTTQL YTDRTKLRP EMEGPGSFTI FAPSNEAWAS
 151 LPAEVLDSLVS SNVNIELLNA LRYHVMVGRV LTDELKHGMT LTSMYQNSNI
 201 QIHHYPNGIV TVNCARLLKA DHATNGVVH LIDKVISITIT NNIQQIIEIE
 251 DTFETLRAAV AASGLNTMLE GNGQYTLAP TNEAFERIPS ETLNRIILGDP
 301 EALRDLNNH ILKSAMCAEA IVAGLSVETL EGTTLLEVGS GDMLTINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFRQAGL
 401 GNHLGSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
 451 HGQTLETGG KKLRFVYVRN SLCIENS CIA AHDKRGRYGT LFTMDRVLTLP
 501 PMGTVMVDLV GDNRFMSLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
 551 PPRERSRLLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGGKLEVS
 601 LKNNVVSVNK EPVAEPDIMA TNGVVHVIIN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

L34 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:441937 CAPLUS <<LOGINID::20081002>>

DOCUMENT NUMBER: 133:85149

TITLE: Colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer

INVENTOR(S): Xu, Jiangchun; Lodes, Michael J.; Secrist, Heather; Benson, Darin R.; Meagher, Madeleine Joy; Stolk, John; Wang, Tongtong; Jiang, Yuqiu

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 229 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037643	A2	20000629	WO 1999-US30909	19991223 <--
WO 2000037643	A3	20010809		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6284241	B1	20010904	US 1998-221298	19981223 <--
US 6623923	B1	20030923	US 1999-401064	19990922 <--
CA 2356987	A1	20000629	CA 1999-2356987	19991223 <--
EP 1144632	A2	20011017	EP 1999-967625	19991223 <--
EP 1144632	A3	20011107		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002533082	T	20021008	JP 2000-589697	19991223 <--
US 20020110547	A1	20020815	US 2001-833263	20010410 <--
US 20020076414	A1	20020620	US 2001-922217	20010803 <--

US 20020182191	A1	20021205	US 2001-25380	20011219 <--
US 20050260177	A1	20051124	US 2005-108172	20050415 <--
PRIORITY APPLN. INFO.:			US 1998-221298	A 19981223 <--
			US 1999-347496	A 19990702 <--
			US 1999-401064	A 19990922 <--
			US 1999-444242	A 19991119 <--
			US 1999-454150	A 19991202 <--
			US 1999-444252	A2 19991119 <--
			WO 1999-US30909	W 19991223 <--
			US 1999-476296	A2 19991230 <--
			US 2000-480321	A2 20000110 <--
			US 2000-504629	A2 20000215 <--
			US 2000-519444	A2 20000306 <--
			US 2000-444252	A2 20000410 <--
			US 2000-575251	A2 20000519 <--
			US 2000-609448	A2 20000629 <--
			US 2000-649811	A2 20000828 <--
			US 2001-833263	A2 20010410 <--
			US 2001-922217	A2 20010803 <--
			US 2001-25380	B1 20011219 <--

AB Over 470 nucleic acids that are overexpressed ≥ 2 -fold in human colon tumor tissues are provided. Complementary DNA libraries were constructed by subtracting a pool of colon tumors with a pool of normal colon and other tissues using PCR subtraction methodologies; clones from the cDNA subtracted library were submitted to PCR amplification, and mRNA expression levels for representative clones determined by microarray technol. This method recovers rare transcripts that are over-expressed in colon tumor tissue. Addnl. colon tumor-specific transcripts were obtained by (1) conventional cDNA subtraction, (2) use of mouse antisera to identify DNA sequences encoding colon tumor antigens, (3) and isolation of tumor polypeptides using SCID-passaged tumor RNA. Compns. and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compns. may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen-presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT 148710-76-3, Protein (human clone pig-h3 transforming growth factor β -induced precursor reduced)
 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (amino acid sequence; colon tumor-specific nucleic acids and proteins and their use for immunotherapy and diagnosis of colon cancer)

RN 148710-76-3 CAPLUS

CN Protein (human clone pig-h3 transforming growth factor β -induced precursor reduced) (9CI) (CA INDEX NAME)

SEQ 1 MALFVRLAL ALALALGPAA TLAGPAKSPY QLVLQHSRLR GRQHGPNVCA
 51 VQKVIGTNRK YFTNCKQWYQ RKICGKSTVI SYECCPGYEK VPEKGCPAA
 101 LPLSNLYETL GVGSGTTTQL YDRTTEKLRP EMEGPGSFTI FAPSNEAWAS
 151 LPAEVLDSLIV SNVNIELLNA LRYHMVGRVR LTDELKHGMT LTSMYQNSNI
 201 QIHHPNGIV TVNCARLLKA DHHTATNGVVH LIDKVISITIT NNIQIQTIEIE
 251 DTFTETLRAAV AASGLNTMLE GNGQYTLAP TNEAFEKIPS ETLNRLGDP
 301 EALRDLNNNH ILKSAMCAEA IVAGLSVETL EGTTELVGCS GDMLTINGKA
 351 IISNKDILAT NGVIHYIDEL LIPDSAKTLF ELAAESDVST AIDLFQRAGL

401 GNHLSGSERL TLLAPLNSVF KDGTPPIDAH TRNLLRNHII KDQLASKYLY
 451 HGQTLETGG KKLRFVYRN SLCIENSCIA AHDKRGRYGT LFTMDRVLTPT
 501 PMGTVMVLK GDNRFSLVA AIQSAGLTET LNREGVYTVF APTNEAFRAL
 551 PPRERSRLG DAKELANILK YHIGDEILVS GGIGALVRLK SLQGGKLEVS
 601 LKNNVSVNK EPVAEPDIMA TNGVVHVITN VLQPPANRPQ ERGDELADSA
 651 LEIFKQASAF SRASQRSVRL APVYQKLLER MKH

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	199.12	324.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-16.00	-16.00

FILE 'STNGUIDE' ENTERED AT 14:31:27 ON 02 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 26, 2008 (20080926/UP).

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.18	324.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-16.00

FILE 'CAPLUS' ENTERED AT 14:33:20 ON 02 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14
 FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d his

(FILE 'HOME' ENTERED AT 14:15:35 ON 02 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:23:09 ON 02 OCT 2008

L1 67 S IELLNALRYHMGRRVLT/SQSP
L2 84 S EALRDLNNHILKSAMCA/SQSP
L3 58 S DQLASKYLYHGQTLETG/SQSP
L4 68 S KELANILKYHIGDEILVS/SQSP

FILE 'CAPLUS' ENTERED AT 14:23:34 ON 02 OCT 2008

L5 68 S L1
L6 68 S L2
L7 58 S L3
L8 58 S L4

FILE 'STINGUIDE' ENTERED AT 14:24:26 ON 02 OCT 2008

L9 5 S CANCER

FILE 'CAPLUS' ENTERED AT 14:25:26 ON 02 OCT 2008

L10 246905 S CANCER
L11 155786 S CARCINOMA
L12 45688 S ONCO?
L13 546919 S NEOPLAS?
L14 297654 S TUMOR OR TUMOUR
L15 40146 S ANGIOGEN?
L16 11213 S ARTERIOSCLER?
L17 25778 S SCLEROSIS
L18 52 S NEOVASCULAR GLAUCOMA
L19 5164 S DIABETIC RETINOPATHY
L20 227 S PTERYGIUM
L21 1185 S RETINAL DEGENERATION
L22 617 S RETROLENTAL FIBROPLASIA
L23 1 S GRANULAR CONJUNCTIVITIS
L24 26118 S RHEUMATOID ARTHRITIS
L25 17699 S LUPUS
L26 71761 S THYROID?
L27 15306 S PSORIASIS
L28 28 S PYOGENIC GRANULOMA
L29 158 S SEBORRHEIC DERMATITIS
L30 7117 S ACNE
L31 914566 S L10-L30
L32 78 S L5-L8
L33 31 S L32(L)L31
L34 20 S L33 AND (PD<20030402 OR AD<20030402 OR PRD<20030402)

FILE 'STINGUIDE' ENTERED AT 14:31:27 ON 02 OCT 2008

FILE 'CAPLUS' ENTERED AT 14:33:20 ON 02 OCT 2008

=> s l31 and l32
L35 47 L31 AND L32

=> s l35 and (pd<20030402 or ad<20030402 or prd<20030402)
L36 32 L35 AND (PD<20030402 OR AD<20030402 OR PRD<20030402)

=> s l36 not l34
L37 12 L36 NOT L34

=> d ti 1-12

- L37 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases
- L37 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
- L37 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Use of patterns of gene expression to identify tissue types and in disease diagnosis and prognosis
- L37 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Methods of testing for bronchial asthma or chronic obstructive pulmonary disease, and drug screening for the same, using identified differentially expressed IL-13-stimulated marker genes
- L37 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics
- L37 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Method for measuring the amount of protein β ig-h3 and diagnostic kit using the same
- L37 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Complexes of human and human papillomavirus proteins and their use in drug screening and diagnosis
- L37 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Genes that are differentially expressed during erythropoiesis and their diagnostic and therapeutic uses
- L37 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses
- L37 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Transforming growth factor (TGF- β)-induced expression of gene for protein β IG-H3 in human cells
- L37 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI β ig-h3: a transforming growth factor- β -responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice
- L37 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
TI Transforming growth factor β (TGF- β)-induced gene expression

=> d ibib abs 1-12

- L37 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:482032 CAPLUS <LOGINID::20081002>
DOCUMENT NUMBER: 141:37605
TITLE: Gene expression profile in activated human CD4+ T cells useful for the diagnosis and treatment of immune-related diseases

INVENTOR(S): Clark, Hilary; Hunte, Bridsell; Jackman, Janet;
Schoenfeld, Jill; Williams, Mickey P.; Wood, William
I.; Wu, Thomas D.; Bodary, Sarah
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 8598 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004047728	A2	20040610	WO 2003-XA35971	20031124 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004047728	A2	20040610	WO 2003-US35971	20031124 <--
WO 2004047728	A3	20061130		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2002-429069P	P 20021126 <--
			WO 2003-US35971	A 20031124

AB The present invention relates to comps. containing novel proteins and methods of using those comps. for the diagnosis and treatment of immune-related diseases. Microarray anal. of human CD4+ T-cells activated with an anti-CD3 antibody together with either ICAM-1 or anti-CD28 antibody provides genes that are differentially expressed in comparison to resting CD4+ T-cells. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L37 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:449883 CAPLUS <<LOGINID:20081002>>
DOCUMENT NUMBER: 140:402911
TITLE: Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
INVENTOR(S): Nevins, Joseph R.; West, Mike; Huang, Andrew T.
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 886 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038376	A2	20040506	WO 2003-XA33946	20031024 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004038376	A2	20040506	WO 2003-US33946	20031024 <--
WO 2004038376	A3	20040826		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2002-420729P	P	20021024 <--
US 2002-421062P	P	20021025 <--
US 2002-421102P	P	20021025 <--
US 2002-424701P	P	20021108 <--
US 2002-424715P	P	20021108 <--
US 2002-424718P	P	20021108 <--
US 2002-425256P	P	20021112 <--
US 2003-448461P	P	20030221 <--
US 2003-448462P	P	20030221 <--
US 2003-457877P	P	20030327 <--
US 2003-458373P	P	20030331 <--
WO 2003-US33946	A	20031024

AB The statistical anal. described and claimed is a predictive statistical tree model that overcomes several problems observed in prior statistical models and regression analyses, while ensuring greater accuracy and predictive capabilities. Although the claimed use of the predictive statistical tree model described herein is directed to the prediction of a disease in individuals, the claimed model can be used for a variety of applications including the prediction of disease states, susceptibility of disease states or any other biol. state of interest, as well as other applicable non-biol. states of interest. This model first screens genes to reduce noise, applies kmeans correlation-based clustering targeting a large number of clusters, and then uses singular value decompns. (SVD) to extract the single dominant factor (principal component) from each cluster. This generates a statistically significant number of cluster-derived singular factors, that are referred to as metagenes, that characterize multiple patterns of expression of the genes across samples. The strategy aims to extract multiple such patterns while reducing dimension and smoothing out gene-specific noise through the aggregation within clusters. Formal predictive anal. then uses these metagenes in a Bayesian classification tree anal. This generates multiple recursive partitions of the sample into subgroups (the 'leaves' of the classification tree), and assoc. Bayesian predictive probabilities of outcomes with each subgroup. Overall predictions for an individual sample are then generated by averaging predictions, with appropriate wts., across many such tree models. The model includes the use of iterative out-of-sample, cross-validation

predictions leaving each sample out of the data set one at a time, refitting the model from the remaining samples and using it to predict the hold-out case. This rigorously tests the predictive value of a model and mirrors the real-world prognostic context where prediction of new cases as they arise is the major goal.

L37 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:219931 CAPLUS <<LOGINID::20081002>>
 DOCUMENT NUMBER: 140:248186
 TITLE: Use of patterns of gene expression to identify tissue types and in disease diagnosis and prognosis
 INVENTOR(S): Glinskii, Guennadi V.
 PATENT ASSIGNEE(S): Sidney Kimmel Cancer Center, USA
 SOURCE: U.S. Pat. Appl. Publ., 209 pp., which which which which
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040053317	A1	20040318	US 2003-660434	20030910 <--
CA 2498418	A1	20040325	CA 2003-2498418	20030910 <--
WO 2004025258	A2	20040325	WO 2003-US28707	20030910 <--
WO 2004025258	A3	20050519		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003274970	A1	20040430	AU 2003-274970	20030910 <--
EP 1552293	A2	20050713	EP 2003-759240	20030910 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050142573	A1	20050630	US 2004-861003	20040603 <--
PRIORITY APPLN. INFO.:				
			US 2002-410018P	P 20020910 <--
			US 2002-411155P	P 20020916 <--
			US 2002-429168P	P 20021125 <--
			US 2003-444348P	P 20030131 <--
			US 2003-460826P	P 20030403
			US 2003-660434	A1 20030910
			WO 2003-US28707	W 20030910
AB Methods of using quant. anal. of array hybridizations to identify normal and diseased tissue in the diagnosis and prognosis of disease are described. The methods segregate individual samples into distinct classes using quant. measurements of expression values for selected sets of genes in individual samples compared to a reference standard Samples displaying pos. and neg. correlations of the gene expression values with the reference standard samples exhibit distinct behaviors and pathohistol. features. Also disclosed are methods for identifying sets of genes whose expression patterns are correlated with a phenotype. Such sets are useful for characterizing cellular differentiation pathways and states and for identifying potential				

drug discovery targets. Panels for diagnosis and determination of risk of invasive and metastatic forms of lung, prostate and breast cancer are identified. Similarly, panels indicating recurrence of the cancers and poor prognostic outcomes are identified.

L37 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:181844 CAPLUS <<LOGINID::20081002>>

DOCUMENT NUMBER: 140:233978

TITLE: Methods of testing for bronchial asthma or chronic obstructive pulmonary disease, and drug screening for the same, using identified differentially expressed IL-13-stimulated marker genes

INVENTOR(S): Ohtani, Noriko; Sugita, Yuji; Yamaya, Mutsuo; Kubo, Hiroshi; Nagai, Hiroichi; Izuhara, Kenji

PATENT ASSIGNEE(S): Genox Research, Inc., Japan

SOURCE: Eur. Pat. Appl., 241 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1394274	A2	20040303	EP 2003-254857	20030804 <--
EP 1394274	A3	20040526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004121218	A	20040422	JP 2003-77212	20030320 <--
US 20050208496	A1	20050922	US 2003-631467	20030731 <--
PRIORITY APPLN. INFO.:			JP 2002-229312	A 20020806 <--
			JP 2003-77212	A 20030320 <--

AB An objective of the present invention is to provide a method of testing for bronchial asthma or chronic obstructive pulmonary disease, a method of screening for candidate compds. for treating bronchial asthma or chronic obstructive pulmonary disease, and a pharmaceutical agent for treating bronchial asthma or chronic obstructive pulmonary disease. The present invention identified genes whose expression levels varied between respiratory epithelial cells that had been stimulated by IL-13 to induce the goblet cell differentiation, and unstimulated respiratory epithelial cells. The respiratory epithelial cells were cultured according to the air interface method. The genes were revealed to be useful as markers for testing for bronchial asthma or chronic obstructive pulmonary disease and screening for therapeutic agents for such diseases. Specifically, the present invention provides methods of testing for bronchial asthma or chronic obstructive pulmonary disease and methods of screening for compds. to treat the diseases based on the comparison of the expression levels of marker genes identified as described above.

L37 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:942764 CAPLUS <<LOGINID::20081002>>

DOCUMENT NUMBER: 140:3792

TITLE: Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics

INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal

PATENT ASSIGNEE(S): Duke University, USA

SOURCE: PCT Int. Appl., 408 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XA38221	20021112 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003091391	A2	20031106	WO 2002-US38221	20021112 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2002-374547P	P 20020423 <--
			US 2002-420784P	P 20021024 <--
			US 2002-421043P	P 20021025 <--
			US 2002-424680P	P 20021108 <--
			WO 2002-US38221	A 20021112 <--

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using a Bayesian anal.

L37 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:856144 CAPLUS <<LOGINID:20081002>>

DOCUMENT NUMBER: 139:347737

TITLE: Method for measuring the amount of protein β ig-h3 and diagnostic kit using the same

INVENTOR(S): Kim, In-San; Bae, Jong-Sub

PATENT ASSIGNEE(S): Regen Biotech, Inc., S. Korea

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089935	A1	20031030	WO 2002-KR1975	20021022 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,			

UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

KR 2002082421 A 20021031 KR 2002-21488 20020419 <--
 AU 2002348583 A1 20031103 AU 2002-348583 20021022 <--
 AU 2002348583 B2 20061207
 EP 1502114 A1 20050202 EP 2002-781971 20021022 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002015700 A 20050503 BR 2002-15700 20021022 <--
 CN 1625687 A 20050608 CN 2002-828782 20021022 <--
 CN 100374864 C 20080312
 JP 2005527813 T 20050915 JP 2003-586617 20021022 <--
 RU 2281512 C2 20060810 RU 2004-133806 20021022 <--
 US 20050164197 A1 20050728 US 2004-511719 20041126 <--
 PRIORITY APPLN. INFO.: KR 2002-21488 A 20020419 <--
 KR 2001-20991 A 20010419 <--
 WO 2002-KR1975 W 20021022 <--

AB The present invention relates to the method for measuring the amount of β ig-h3 protein and diagnostic kit using the same. The β ig-h3 protein is an extracellular matrix protein involved in cell adhesion, is induced by TGF- β in many kinds of cells, and contains fas-l domains composed of 110-140 amino acids containing two very conserved branches composed of 10 amino acids each. Particularly, the invention relates to the method for measuring the amount of β ig-h3 protein in the body fluids by specific binding reaction between β ig-h3 protein or recombinant proteins of the fas-l domain in β ig-h3 protein (including their fragments or their derivs.) and their ligands, in particular an antigen-antibody reaction. Sensitive diagnostic kits for renal diseases, hepatic diseases, rheumatoid arthritis, or cardiovascular diseases are thus provided. Standard protein can be any of human β ig-h3, mouse β ig-h3, recombinant β ig-h3 D-IV(1x) which is a monomer of the fourth fas-l domain, ig-h3 D-IV(2x), ig-h3 D-IV(3x) and β ig-h3 D-IV(4x), and either anti-human β ig-h3 antibody or anti-mouse β ig-h3 antibody can be used as the primary antibody. The preferable coating concn of std protein is 0.1-2.0 μ g/mL and 0.5-1.0 μ g/mL is more preferable; and the preferable diluting ratio of the primary and the secondary antibody is 1:400-1:3200 and 1:2000 is more preferable.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2003:656897 CAPLUS <LOGINID:20081002>
 DOCUMENT NUMBER: 139:193297
 TITLE: Complexes of human and human papillomavirus proteins and their use in drug screening and diagnosis
 INVENTOR(S): Jackson, Amanda; Ooi, Chean Eng; Lewin, David A.; Cuthill, Scott
 PATENT ASSIGNEE(S): Curagen Corporation, USA; Hoffmann-La Roche Inc.
 SOURCE: PCT Int. Appl., 156 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068940	A2	20030821	WO 2003-US4594	20030214 <--

WO 2003068940 A3 20031127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003215244 A1 20030904 AU 2003-215244 20030214 <--
US 20050100554 A1 20050512 US 2003-367057 20030214 <--

PRIORITY APPLN. INFO.: US 2002-356911P P 20020214 <--
WO 2003-US4594 W 20030214 <--

AB Complexes of human papillomavirus (HPV) proteins E1-E7, L1, and L2 with human proteins are disclosed. These complexes may be used to screen for agents which disrupt the complexes. These agents may be used for treatment of HPV infections. A method of detecting these complexes may be used in screening for pre-cancerous cervical lesions and for classifying HPV infections. Thus, yeast two-hybrid assays were used to identify interactions of HPV-1a, HPV-11, and HPV-16 proteins with human proteins.

L37 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2003:409169 CAPLUS <LOGINID:20081002>

DOCUMENT NUMBER: 138:380506

TITLE: Genes that are differentially expressed during erythropoiesis and their diagnostic and therapeutic uses

INVENTOR(S): Brissette, William H.; Neote, Kuldeep S.; Zagouras, Panayiotis; Zenke, Martin; Lemke, Britt; Hacker, Christine

PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Max-Delbrueck-Centrum Fuer Molekulare Medizin

SOURCE: PCT Int. Appl., 285 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003038130	A2	20030508	WO 2002-XA34888	20021031 <--
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,				
NE, SN, TD, TG				
WO 2003038130	A2	20030508	WO 2002-US34888	20021031 <--
WO 2003038130	A3	20040212		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-335048P P 20011031 <--
 US 2001-335183P P 20011102 <--
 WO 2002-US34888 A 20021031 <--

AB The present invention provides mol. targets that regulate erythropoiesis. Groups of genes or their encoded gene products comprise panels of the invention and may be used in therapeutic intervention, therapeutic agent screening, and in diagnostic methods for diseases and/or disorders of erythropoiesis. The panels were discovered using gene expression profiling of erythroid progenitors with Affymetrix HU6800 and HG-U95Av2 chips. Cells from an in vitro growth and differentiation system of SCF-Epo dependent human erythroid progenitors, E-cadherin+/CD36+ progenitors, cord blood, or CD34+ peripheral blood stem cells were analyzed. The HU6800 chip contains probes from 13,000 genes with a potential role in cell growth, proliferation, and differentiation and the HG-U95Av2 chip contains 12,000 full-length, functionally-characterized genes. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints].

L37 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2002:869107 CAPLUS <<LOGINID:20081002>>
 DOCUMENT NUMBER: 137:364443
 TITLE: Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses
 INVENTOR(S): Alsobrook, John P.; II; Anderson, David W.; Boldog, Ferenc L.; Burgess, Catherine E.; Casman, Stacie J.; Edinger, Schlomit R.; Ellerman, Karen; Gangolli, Esha A.; Gerlach, Valerie L.; Gorman, Linda; Gunther, Erik; Herrmann, John L.; Ji, Weizhen; Lepley, Denise M.; Lewin, David A.; Li, Li; Macdougall, John R.; Malyankar, Uriel M.; Mezes, Peter D.; Padigar, Muralidhara; Patturajan, Meera; Peyman, John A.; Rastelli, Luca; Rieger, Daniel K.; Rothenberg, Mark E.; Shenoy, Suresh G.; Smithson, Glennada; Spytek, Kimberly A.; Stone, David J.; Taupier, Raymond J., Jr.; Tchernev, Velizar T.; Vernet, Corine A. M.; Voss, Edward Z.; Zerhusen, Bryan D.; Zhong, Haihong; Miller, Charles E.
 PATENT ASSIGNEE(S): Curagen Corporation, USA
 SOURCE: PCI Int. Appl., 491 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 175
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002090568	A2	20021114	WO 2002-US14341	20020502 <--
WO 2002090568	A3	20050421		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,			
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,			
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2446427	A1	20021114	CA 2002-2446427 20020502 <--
AU 2002314769	A1	20021118	AU 2002-314769 20020502 <--
JP 2005504514	T	20050217	JP 2002-587627 20020502 <--
EP 1539806	A2	20050615	EP 2002-741692 20020502 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
AU 2005200106	A1	20050210	AU 2005-200106 20050112 <--
AU 2006201467	A1	20060504	AU 2006-201467 20060407 <--
AU 2007202935	A1	20070719	AU 2007-202935 20070626 <--
PRIORITY APPLN. INFO.:			US 2001-288935P P 20010503 <--
			US 2001-289087P P 20010507 <--
			US 2001-289620P P 20010508 <--
			US 2001-289621P P 20010508 <--
			US 2001-289817P P 20010509 <--
			US 2001-289818P P 20010509 <--
			US 2001-290194P P 20010511 <--
			US 2001-290753P P 20010514 <--
			US 2001-291189P P 20010515 <--
			US 2001-291243P P 20010516 <--
			US 2001-292001P P 20010518 <--
			US 2001-292374P P 20010521 <--
			US 2001-292587P P 20010522 <--
			US 2001-293107P P 20010523 <--
			US 2001-293589P P 20010524 <--
			US 2001-293747P P 20010525 <--
			US 2001-294110P P 20010529 <--
			US 2001-294434P P 20010530 <--
			US 2001-312192P P 20010814 <--
			US 2001-313173P P 20010817 <--
			US 2001-313187P P 20010817 <--
			US 2001-318728P P 20010912 <--
			US 2001-318744P P 20010912 <--
			US 2001-335910P P 20011115 <--
			US 2001-333891P P 20011128 <--
			US 2001-333942P P 20011128 <--
			US 2002-345776P P 20020103 <--
			US 2002-345220P P 20020104 <--
			US 2002-136071 A 20020501 <--
			AU 2000-37360 A3 20000309 <--
			AU 2000-78680 A3 20001006 <--
			AU 2001-247294 A3 20010305 <--
			AU 2001-47294 T0 20010305 <--
			US 2001-288395P P 20010503 <--
			WO 2002-US14341 W 20020502 <--

AB Disclosed herein are 62 cDNA sequences that encode novel human polypeptides that are members of the following protein families: trypsin, germline oligomeric matrix protein, neuromedin U25, caldecrin, neural cell adhesion protein, ADAMTS 12, CASPR4, ADAMS-TS3, gliacolin, aminopeptidase N, adiponectin, trypsin III, tissue kallikrein, β -transforming growth factor, diphthamide synthesis protein, WECHE lungkine, ADAM-TS7, palmitoyl-protein thioesterase-2I, betacellulin, small inducible cytokine A23, granulocyte colony-stimulating factor, platelet basic protein 2, brain natriuretic peptide, serine protease, acyl-CoA-binding protein, elastase IV, collagen, viral receptor, and cathepsin L2. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic,

diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

L37 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:810958 CAPLUS <<LOGINID::20081002>>
DOCUMENT NUMBER: 123:219300
ORIGINAL REFERENCE NO.: 123:38838h
TITLE: Transforming growth factor (TGF- β)-induced expression of gene for protein BIG-H3 in human cells
INVENTOR(S): Purchio, Anthony F.; Skonier, John E.; Neubauer, Michael G.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S., 23 pp. Cont.-in-part of U.S. Ser. No. 833,835, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5444164	A	19950822	US 1992-878960	19920504 <--
CA 2088804	A1	19930806	CA 1993-2088804	19930204 <--
ES 2073327	T3	19950801	ES 1993-300809	19930204 <--
JP 07133296	A	19950523	JP 1993-18705	19930205 <--
PRIORITY APPLN. INFO.:			US 1992-833835	B2 19920205 <--

AB Expression of the gene for protein BIG-H3 by TGF- β in human lung adenocarcinoma cells A549 and H2981 is described, its cDNA isolated, and amino acid sequence deduced. The 683-amino-acid protein contains 4 homologous repeats and may represent a cell surface recognition mol. The TGF- β -induced protein shown to inhibit the growth of tumor cells.

L37 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:571807 CAPLUS <<LOGINID::20081002>>
DOCUMENT NUMBER: 121:171807
ORIGINAL REFERENCE NO.: 121:31007a, 31010a
TITLE: β ig-h3: a transforming growth factor- β -responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice
AUTHOR(S): Skonier, John; Bennett, Kelly; Rothwell, Victoria; Kosowski, Steve; Plowman, Greg; Wallace, Phil; Edelhoff, Susanne; Distèche, Christine; Neubauer, Mike; et al.
CORPORATE SOURCE: Pharmaceutical Research Institute, Bristol-Myers Squibb, Seattle, WA, 98121, USA
SOURCE: DNA and Cell Biology (1994), 13(6), 571-584
CODEN: DCEBE8; ISSN: 1044-5498
DOCUMENT TYPE: Journal
LANGUAGE: English

AB β ig-h3 is a novel gene first discovered by differential screening of a cDNA library made from A549 human lung adenocarcinoma cells treated with transforming growth factor- β 1 (TGF- β 1). It encodes a 683-amino-acid protein containing a secretory signal sequence and four homologous internal domains. Here the authors show that treatment of several types of cells, including human melanoma cells, human mammary epithelial cells, human keratinocytes, and human fibroblasts, with TGF- β resulted in a significant increase in β ig-h3 RNA. A

portion of the β ig-h3 coding sequence was expressed in bacteria, and antisera against the bacterially produced protein was raised in rabbits. This antisera was used to demonstrate that several cell lines secreted a 68-kD β IG-H3 protein after treatment with TGF- β . Transfection of β IG-H3 expression plasmids into Chinese hamster ovary (CHO) cells led to a marked decrease in the ability of these cells to form tumors in nude mice. The β IG-H3 protein was purified from media conditioned by recombinant CHO cells, characterized by immunoblotting and protein sequencing and shown to function in an anti-adhesion assay in that it inhibited the attachment of A549, HeLa, and WI-38 cells to plastic in serum-free media. Sequencing of cDNA clones encoding murine β ig-H3 indicated 90.6% conservation at the amino acid level between the murine and human proteins. Finally, the β ig-h3 gene was localized to human chromosome 5q31, a region frequently deleted in preleukemic myelodysplasia and leukemia. The corresponding mouse β ig-h3 gene was mapped to mouse chromosome 13 region B to C1, which confirms a region of conservation on human chromosome 5 and mouse chromosome 13. The authors suggest that this protein be named p68 β ig-h3.

L37 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:618358 CAPLUS <<LOGINID:20081002>>

DOCUMENT NUMBER: 119:218358

ORIGINAL REFERENCE NO.: 119:38717a,38720a

TITLE: Transforming growth factor β (TGF- β)-induced gene expression

INVENTOR(S): Purchio, Anthony F.; Neubauer, Michael G.; Skonier, John E.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: Eur. Pat. Appl., 23 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 555989	A1	19930818	EP 1993-300809	19930204 <--
EP 555989	B1	19950524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2088804	A1	19930806	CA 1993-2088804	19930204 <--
ES 2073327	T3	19950801	ES 1993-300809	19930204 <--
JP 07133296	A	19950523	JP 1993-18705	19930205 <--
PRIORITY APPLN. INFO.:			US 1992-833835	A 19920205 <--

AB TGF- β -induced gene expression is observed in a few cultured mammalian cell lines such as the cell lines derived from human adenocarcinoma cells, the embryonic palatal mesenchyme cells, and prostate adenocarcinoma cells. The cDNA encoding the induced protein is isolated from the TGF- β -treated human lung adenocarcinoma-derived cell line A549 and its amino acid sequence deduced. The protein designated β IG-H3 consists of 4 homologous repeat regions with a total of 683 amino acids. An Arg-Gly-Asp motif at positions 642-644, that may function as a ligand recognition sequence for several integrins, is also noted. Methods for production and identification of the proteins are also claimed.

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

47.04 371.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-9.60	-25.60

FILE 'STNGUIDE' ENTERED AT 14:35:15 ON 02 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Sep 26, 2008 (20080926/UP).

=>		
=> log h		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.00	374.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-25.60

SESSION WILL BE HELD FOR 120 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 15:04:59 ON 02 OCT 2008